<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Trials</journal-id><journal-id journal-id-type="iso-abbrev">Trials</journal-id><journal-title-group><journal-title>Trials</journal-title></journal-title-group><issn pub-type="epub">1745-6215</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26873336</article-id><article-id pub-id-type="pmc">4752791</article-id><article-id pub-id-type="publisher-id">1210</article-id><article-id pub-id-type="doi">10.1186/s13063-016-1210-y</article-id><article-categories><subj-group subj-group-type="heading"><subject>Study Protocol</subject></subj-group></article-categories><title-group><article-title>Study of endothelial function response to exercise training in hypertensive individuals (SEFRET): study protocol for a randomized controlled trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Pedralli</surname><given-names>Marinei Lopes</given-names></name><address><email>marinei.lopespedralli@gmail.com</email></address><xref ref-type="aff" rid="Aff1"></xref><xref ref-type="aff" rid="Aff2"></xref></contrib><contrib contrib-type="author"><name><surname>Waclawovsky</surname><given-names>Gustavo</given-names></name><address><email>gwsaude@yahoo.com.br</email></address><xref ref-type="aff" rid="Aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Camacho</surname><given-names>Augusto</given-names></name><address><email>augusto.santos.cmacho@gmail.com</email></address><xref ref-type="aff" rid="Aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Markoski</surname><given-names>Melissa Medeiros</given-names></name><address><email>melmarkoski@gmail.com</email></address><xref ref-type="aff" rid="Aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Castro</surname><given-names>Iran</given-names></name><address><email>irancstro@gmail.com</email></address><xref ref-type="aff" rid="Aff1"></xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Lehnen</surname><given-names>Alexandre Machado</given-names></name><address><phone>(51) 3230.3600</phone><email>amlehnen@gmail.com</email></address><xref ref-type="aff" rid="Aff1"></xref><xref ref-type="aff" rid="Aff3"></xref></contrib><aff id="Aff1"><label></label>Laboratório de Investigação Clínica, Instituto de Cardiologia / Fundação Universitária de Cardiologia – ICFUC, Av. Princesa Isabel, 395. Bairro Santana, 90620 001 Porto Alegre, RS Brazil </aff><aff id="Aff2"><label></label>Universidade Luterana do Brasil – ULBRA, Torres, Rio Grande do Sul Brazil </aff><aff id="Aff3"><label></label>Faculdade Sogipa de Educação Física, Porto Alegre, Rio Grande do Sul Brazil </aff></contrib-group><pub-date pub-type="epub"><day>13</day><month>2</month><year>2016</year></pub-date><pub-date pub-type="pmc-release"><day>13</day><month>2</month><year>2016</year></pub-date><pub-date pub-type="collection"><year>2016</year></pub-date><volume>17</volume><elocation-id>84</elocation-id><history><date date-type="received"><day>9</day><month>9</month><year>2015</year></date><date date-type="accepted"><day>3</day><month>2</month><year>2016</year></date></history><permissions><copyright-statement>© Pedralli et al. 2016</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title><offsets xml_i="4415" xml_f="4425" txt_i="11" txt_f="21">Background</offsets></title><p><offsets xml_i="4436" xml_f="5005" txt_i="22" txt_f="591">Endothelial dysfunction is a hallmark of diabetes mellitus and systemic arterial hypertension (SAH) and an early maker for atherosclerosis. Aerobic exercise training is known to enhance endothelial function, but little is understood about the effects of resistance or combined exercise training on endothelial function. The aim of this study is to investigate the effect of a 12-week aerobic (AT), resistance (RT), or combined (aerobic and resistance, CT) training program on endothelial function and assess associated effects on blood pressure in individuals with SAH.</offsets></p></sec><sec><title><offsets xml_i="5027" xml_f="5041" txt_i="593" txt_f="607">Methods/design</offsets></title><p><offsets xml_i="5052" xml_f="6255" txt_i="608" txt_f="1811">Eighty-one subjects with SAH aged 18 to 70 years will be selected and randomly assigned to three types of exercise training: AT, RT or CT. The study will involve the following procedures and tests: anamnesis, anthropometric assessment, echocardiography, blood pressure measurements through ambulatory blood pressure monitoring, flow-mediated dilation, ergospirometry, one repetition maximum test (1-RM), and blood collection (number of circulating endothelial progenitor cells, number of circulating endothelial microparticles, lipid profile, glucose, glycated hemoglobin, and creatinine). The AT intervention will consist of a 40-min exercise session with progressive intensities ranging from 50 to 75 % of heart rate reserve. The RT intervention will consist of a 40-minute session with four sets of six to 12 repetitions with a rest period of 60 to 90 seconds between each set and each type of exercise. Weight loads will be adjusted to 60 to 80 % of 1-RM for six types of exercise. The CT intervention will consist of a 20-min aerobic exercise session, followed by an additional 20-min resistance exercise session; each resistance exercise will have two sets less to match the total training volume.</offsets></p></sec><sec><title><offsets xml_i="6277" xml_f="6287" txt_i="1813" txt_f="1823">Discussion</offsets></title><p><offsets xml_i="6298" xml_f="6744" txt_i="1824" txt_f="2270">The study results are expected evidence of cardiovascular protective effects of different types of exercise training through the modulation of endothelial function in hypertensive individuals. Knowing the magnitude of improvement of endothelium-dependent vasodilation for the different types of exercise training can provide scientific evidence for the prescription of exercise programs for vascular protection targeting hypertensive individuals.</offsets></p></sec><sec><title><offsets xml_i="6766" xml_f="6784" txt_i="2272" txt_f="2290">Trial registration</offsets></title><p><offsets xml_i="6795" xml_f="6835" txt_i="2291" txt_f="2331">The Brazilian Clinical Trials Registry (</offsets><ext-link ext-link-type="uri" xlink:href="http://www.ensaiosclinicos.gov.br/"><offsets xml_i="6913" xml_f="6947" txt_i="2331" txt_f="2365">http://www.ensaiosclinicos.gov.br/</offsets></ext-link><offsets xml_i="6958" xml_f="7000" txt_i="2365" txt_f="2407">) under RBR-9ygmdn and dated 1 March 2015.</offsets></p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Endothelial function</kwd><kwd>Exercise training</kwd><kwd>Hypertension</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>© The Author(s) 2016</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title><offsets xml_i="7397" xml_f="7407" txt_i="2416" txt_f="2426">Background</offsets></title><p><offsets xml_i="7418" xml_f="7591" txt_i="2427" txt_f="2600">Cardiovascular diseases are largely determined by multifactorial risk factors that tend to interact and may be present over the course of an individual’s lifetime. Obesity [</offsets><xref ref-type="bibr" rid="CR1"><offsets xml_i="7623" xml_f="7624" txt_i="2600" txt_f="2601">1</offsets></xref><offsets xml_i="7631" xml_f="7633" txt_i="2601" txt_f="2603">, </offsets><xref ref-type="bibr" rid="CR2"><offsets xml_i="7665" xml_f="7666" txt_i="2603" txt_f="2604">2</offsets></xref><offsets xml_i="7673" xml_f="7697" txt_i="2604" txt_f="2628">], physical inactivity [</offsets><xref ref-type="bibr" rid="CR3"><offsets xml_i="7729" xml_f="7730" txt_i="2628" txt_f="2629">3</offsets></xref><offsets xml_i="7737" xml_f="7739" txt_i="2629" txt_f="2631">, </offsets><xref ref-type="bibr" rid="CR4"><offsets xml_i="7771" xml_f="7772" txt_i="2631" txt_f="2632">4</offsets></xref><offsets xml_i="7779" xml_f="7806" txt_i="2632" txt_f="2659">], and insulin resistance [</offsets><xref ref-type="bibr" rid="CR5"><offsets xml_i="7838" xml_f="7839" txt_i="2659" txt_f="2660">5</offsets></xref><offsets xml_i="7846" xml_f="8004" txt_i="2660" txt_f="2818">] are all risk factors closely associated with systemic arterial hypertension (SAH) and diabetes mellitus type 2. In addition to these risk factors, smoking [</offsets><xref ref-type="bibr" rid="CR6"><offsets xml_i="8036" xml_f="8037" txt_i="2818" txt_f="2819">6</offsets></xref><offsets xml_i="8044" xml_f="8065" txt_i="2819" txt_f="2840">] and excess weight [</offsets><xref ref-type="bibr" rid="CR7"><offsets xml_i="8097" xml_f="8098" txt_i="2840" txt_f="2841">7</offsets></xref><offsets xml_i="8105" xml_f="8146" txt_i="2841" txt_f="2882">] contribute to endothelial dysfunction [</offsets><xref ref-type="bibr" rid="CR8"><offsets xml_i="8178" xml_f="8179" txt_i="2882" txt_f="2883">8</offsets></xref><offsets xml_i="8186" xml_f="8188" txt_i="2883" txt_f="2885">, </offsets><xref ref-type="bibr" rid="CR9"><offsets xml_i="8220" xml_f="8221" txt_i="2885" txt_f="2886">9</offsets></xref><offsets xml_i="8228" xml_f="8273" txt_i="2886" txt_f="2931">], which is a hallmark of diabetes mellitus [</offsets><xref ref-type="bibr" rid="CR10"><offsets xml_i="8306" xml_f="8308" txt_i="2931" txt_f="2933">10</offsets></xref><offsets xml_i="8315" xml_f="8326" txt_i="2933" txt_f="2944">] and SAH [</offsets><xref ref-type="bibr" rid="CR11"><offsets xml_i="8359" xml_f="8361" txt_i="2944" txt_f="2946">11</offsets></xref><offsets xml_i="8368" xml_f="8410" txt_i="2946" txt_f="2988">] and an early maker for atherosclerosis [</offsets><xref ref-type="bibr" rid="CR12"><offsets xml_i="8443" xml_f="8445" txt_i="2988" txt_f="2990">12</offsets></xref><offsets xml_i="8452" xml_f="8454" txt_i="2990" txt_f="2992">].</offsets></p><p><offsets xml_i="8461" xml_f="8551" txt_i="2993" txt_f="3083">The endothelium is a single layer of cells that lines the tunica intima of blood vessels [</offsets><xref ref-type="bibr" rid="CR13"><offsets xml_i="8584" xml_f="8586" txt_i="3083" txt_f="3085">13</offsets></xref><offsets xml_i="8593" xml_f="8722" txt_i="3085" txt_f="3214">] and plays a major role in the modulation of vascular angiogenesis, inflammatory responses, and vascular tone and permeability [</offsets><xref ref-type="bibr" rid="CR14"><offsets xml_i="8755" xml_f="8757" txt_i="3214" txt_f="3216">14</offsets></xref><offsets xml_i="8764" xml_f="8919" txt_i="3216" txt_f="3371">]. Vascular protection is particularly attributable to endothelial nitric oxide synthase (eNOS), an enzyme involved in the production of nitric oxide (NO).</offsets></p><p><offsets xml_i="8926" xml_f="9040" txt_i="3372" txt_f="3486">The balance between endothelial injury and recovery is critical to continuously maintaining endothelial function [</offsets><xref ref-type="bibr" rid="CR15"><offsets xml_i="9073" xml_f="9075" txt_i="3486" txt_f="3488">15</offsets></xref><offsets xml_i="9082" xml_f="9324" txt_i="3488" txt_f="3730">]. The bone marrow releases a progenitor cell subtype called endothelial progenitor cells (EPCs), which have the ability to migrate to the peripheral circulation and differentiate into mature endothelial cells to maintain vascular integrity [</offsets><xref ref-type="bibr" rid="CR16"><offsets xml_i="9357" xml_f="9359" txt_i="3730" txt_f="3732">16</offsets></xref><offsets xml_i="9366" xml_f="9435" txt_i="3732" txt_f="3801">]. EPC levels have been associated with cardiovascular risk factors [</offsets><xref ref-type="bibr" rid="CR17"><offsets xml_i="9468" xml_f="9470" txt_i="3801" txt_f="3803">17</offsets></xref><offsets xml_i="9477" xml_f="9516" txt_i="3803" txt_f="3842">], endothelium-dependent vasodilation [</offsets><xref ref-type="bibr" rid="CR18"><offsets xml_i="9549" xml_f="9551" txt_i="3842" txt_f="3844">18</offsets></xref><offsets xml_i="9558" xml_f="9642" txt_i="3844" txt_f="3928">], and clinical outcomes, including hospitalization and cardiovascular death rates [</offsets><xref ref-type="bibr" rid="CR19"><offsets xml_i="9675" xml_f="9677" txt_i="3928" txt_f="3930">19</offsets></xref><offsets xml_i="9684" xml_f="9745" txt_i="3930" txt_f="3991">]. In patients with cardiovascular risk factors such as SAH [</offsets><xref ref-type="bibr" rid="CR20"><offsets xml_i="9778" xml_f="9780" txt_i="3991" txt_f="3993">20</offsets></xref><offsets xml_i="9787" xml_f="9799" txt_i="3993" txt_f="4005">], smoking [</offsets><xref ref-type="bibr" rid="CR21"><offsets xml_i="9832" xml_f="9834" txt_i="4005" txt_f="4007">21</offsets></xref><offsets xml_i="9841" xml_f="9864" txt_i="4007" txt_f="4030">], metabolic syndrome [</offsets><xref ref-type="bibr" rid="CR22"><offsets xml_i="9897" xml_f="9899" txt_i="4030" txt_f="4032">22</offsets></xref><offsets xml_i="9906" xml_f="9931" txt_i="4032" txt_f="4057">] and diabetes mellitus [</offsets><xref ref-type="bibr" rid="CR23"><offsets xml_i="9964" xml_f="9966" txt_i="4057" txt_f="4059">23</offsets></xref><offsets xml_i="9973" xml_f="10305" txt_i="4059" txt_f="4391">], circulating levels of EPCs can be reduced compared with healthy individuals of matching age and sex. Endothelial dysfunction has been associated with a decreased number and impaired function of EPCs in patients with SAH, diabetes mellitus, and metabolic syndrome, and thus an increased risk of atherosclerosis would be expected [</offsets><xref ref-type="bibr" rid="CR24"><offsets xml_i="10338" xml_f="10340" txt_i="4391" txt_f="4393">24</offsets></xref><offsets xml_i="10347" xml_f="10349" txt_i="4393" txt_f="4395">].</offsets></p><p><offsets xml_i="10356" xml_f="10572" txt_i="4396" txt_f="4612">On the other hand, regular exercise, also known as exercise training, produces effects on the cardiovascular system and has been proven to restore endothelial function even in the presence of cardiovascular disease [</offsets><xref ref-type="bibr" rid="CR25"><offsets xml_i="10605" xml_f="10607" txt_i="4612" txt_f="4614">25</offsets></xref><offsets xml_i="10614" xml_f="10863" txt_i="4614" txt_f="4863">]. Regular exercise promotes changes in cholesterol levels and its subfractions; accelerates the removal of chylomicrons and low-density lipoproteins from circulation; increases the release of NO that seems to generate increased expression of eNOS [</offsets><xref ref-type="bibr" rid="CR26"><offsets xml_i="10896" xml_f="10898" txt_i="4863" txt_f="4865">26</offsets></xref><offsets xml_i="10905" xml_f="10973" txt_i="4865" txt_f="4933">]; increases the number of circulating EPCs in healthy individuals [</offsets><xref ref-type="bibr" rid="CR27"><offsets xml_i="11006" xml_f="11008" txt_i="4933" txt_f="4935">27</offsets></xref><offsets xml_i="11015" xml_f="11085" txt_i="4935" txt_f="5005">], as well as in individuals with established cardiovascular disease [</offsets><xref ref-type="bibr" rid="CR28"><offsets xml_i="11118" xml_f="11120" txt_i="5005" txt_f="5007">28</offsets></xref><offsets xml_i="11127" xml_f="11159" txt_i="5007" txt_f="5039">]; and improves plasma glucose [</offsets><xref ref-type="bibr" rid="CR29"><offsets xml_i="11192" xml_f="11194" txt_i="5039" txt_f="5041">29</offsets></xref><offsets xml_i="11201" xml_f="11262" txt_i="5041" txt_f="5102">], which has a direct link to impaired endothelial function [</offsets><xref ref-type="bibr" rid="CR30"><offsets xml_i="11295" xml_f="11297" txt_i="5102" txt_f="5104">30</offsets></xref><offsets xml_i="11304" xml_f="11375" txt_i="5104" txt_f="5175">]. This assumption is consistent with findings in healthy individuals [</offsets><xref ref-type="bibr" rid="CR31"><offsets xml_i="11408" xml_f="11410" txt_i="5175" txt_f="5177">31</offsets></xref><offsets xml_i="11417" xml_f="11463" txt_i="5177" txt_f="5223">], individuals with diabetes mellitus type 2 [</offsets><xref ref-type="bibr" rid="CR32"><offsets xml_i="11496" xml_f="11498" txt_i="5223" txt_f="5225">32</offsets></xref><offsets xml_i="11505" xml_f="11553" txt_i="5225" txt_f="5273">], and patients with cardiovascular conditions [</offsets><xref ref-type="bibr" rid="CR33"><offsets xml_i="11586" xml_f="11588" txt_i="5273" txt_f="5275">33</offsets></xref><offsets xml_i="11595" xml_f="11675" txt_i="5275" txt_f="5355">], showing that exercise training improved vascular function and overall health.</offsets></p><p><offsets xml_i="11682" xml_f="12156" txt_i="5356" txt_f="5830">Evidence with clinical relevance exists on the impact of aerobic exercise on BP and blood glucose levels, but no consensus exists regarding the effects of resistance training and even less evidence is available on combined training (resistance and aerobic) and the regulatory mechanisms of endothelial function and its relationship with BP in hypertensive individuals. Thus, despite present evidence showing the benefits of exercise and physical training on blood pressure [</offsets><xref ref-type="bibr" rid="CR34"><offsets xml_i="12189" xml_f="12191" txt_i="5830" txt_f="5832">34</offsets></xref><offsets xml_i="12198" xml_f="12226" txt_i="5832" txt_f="5860">] and blood glucose levels [</offsets><xref ref-type="bibr" rid="CR35"><offsets xml_i="12259" xml_f="12261" txt_i="5860" txt_f="5862">35</offsets></xref><offsets xml_i="12268" xml_f="12428" txt_i="5862" txt_f="6022">], more studies are needed to investigate further the mechanisms involved with endothelial function especially their relationship with blood pressure reduction.</offsets></p><p><offsets xml_i="12435" xml_f="12778" txt_i="6023" txt_f="6366">The objective of this study is to evaluate the chronic effects of exercise training on endothelial function modulation in hypertensive patients undergoing a 12-week exercise intervention of aerobic, resistance, or combined (aerobic and resistance) training. Modulation of endothelial function will be assessed by flow-mediated dilation (FMD) [</offsets><xref ref-type="bibr" rid="CR36"><offsets xml_i="12811" xml_f="12813" txt_i="6366" txt_f="6368">36</offsets></xref><offsets xml_i="12820" xml_f="12839" txt_i="6368" txt_f="6387">] and biochemical [</offsets><xref ref-type="bibr" rid="CR37"><offsets xml_i="12872" xml_f="12874" txt_i="6387" txt_f="6389">37</offsets></xref><offsets xml_i="12881" xml_f="12908" txt_i="6389" txt_f="6416">] and cellular parameters [</offsets><xref ref-type="bibr" rid="CR38"><offsets xml_i="12941" xml_f="12943" txt_i="6416" txt_f="6418">38</offsets></xref><offsets xml_i="12950" xml_f="12952" txt_i="6418" txt_f="6420">, </offsets><xref ref-type="bibr" rid="CR39"><offsets xml_i="12985" xml_f="12987" txt_i="6420" txt_f="6422">39</offsets></xref><offsets xml_i="12994" xml_f="13061" txt_i="6422" txt_f="6489">]. The primary and secondary study objectives are listed in Tables </offsets><xref rid="Tab1" ref-type="table"><offsets xml_i="13095" xml_f="13096" txt_i="6489" txt_f="6490">1</offsets></xref><offsets xml_i="13103" xml_f="13108" txt_i="6490" txt_f="6495"> and </offsets><xref rid="Tab2" ref-type="table"><offsets xml_i="13142" xml_f="13143" txt_i="6495" txt_f="6496">2</offsets></xref><offsets xml_i="13150" xml_f="13165" txt_i="6496" txt_f="6511">, respectively.</offsets><table-wrap id="Tab1"><label><offsets xml_i="13194" xml_f="13201" txt_i="6511" txt_f="6518">Table 1</offsets></label><caption><p><offsets xml_i="13221" xml_f="13252" txt_i="6518" txt_f="6549">Primary objectives of the study</offsets></p></caption><table frame="hsides" rules="groups"><tbody><tr><td><offsets xml_i="13318" xml_f="13444" txt_i="6550" txt_f="6676">• To investigate the effects of AT, RT and CT on flow-mediated vasodilation of the brachial artery in hypertensive individuals</offsets><break></break><offsets xml_i="13459" xml_f="13668" txt_i="6676" txt_f="6885">• To assess the impact of different types of training (AT, RT, and CT) on the number of circulating endothelial progenitor cells and number of circulating endothelial microparticles in hypertensive individuals</offsets></td><td></td></tr></tbody></table><table-wrap-foot><p><offsets xml_i="13723" xml_f="13793" txt_i="6887" txt_f="6957">AT, aerobic training; RT, resistance training; CT, concurrent training</offsets></p></table-wrap-foot></table-wrap><table-wrap id="Tab2"><label><offsets xml_i="13857" xml_f="13864" txt_i="6958" txt_f="6965">Table 2</offsets></label><caption><p><offsets xml_i="13884" xml_f="13917" txt_i="6965" txt_f="6998">Secondary objectives of the study</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><th><offsets xml_i="13983" xml_f="14082" txt_i="6999" txt_f="7098">To assess the effectiveness of different types of training (AT, RT and CT) regarding the following:</offsets></th><th></th></tr></thead><tbody><tr><td><offsets xml_i="14124" xml_f="14177" txt_i="7098" txt_f="7151">• Blood pressure levels: clinical assessment and ABPM</offsets><break></break><offsets xml_i="14192" xml_f="14255" txt_i="7151" txt_f="7214">• Serum levels of total cholesterol, HDL, LDL and triglycerides</offsets><break></break><offsets xml_i="14270" xml_f="14317" txt_i="7214" txt_f="7261">• Fasting blood glucose and glycated hemoglobin</offsets><break></break><offsets xml_i="14332" xml_f="14412" txt_i="7261" txt_f="7341">• Blood viscosity, RBC deformability, RBC aggregation, fibrinogen levels and ESR</offsets><break></break><offsets xml_i="14427" xml_f="14505" txt_i="7341" txt_f="7419">• Echocardiography for determination of heart chamber sizes and wall thickness</offsets><break></break><offsets xml_i="14520" xml_f="14580" txt_i="7419" txt_f="7479">• Functional capacity through maximum oxygen consumption (VO</offsets><sub><offsets xml_i="14585" xml_f="14586" txt_i="7479" txt_f="7480">2</offsets></sub><offsets xml_i="14592" xml_f="14596" txt_i="7480" txt_f="7484">max)</offsets><break></break><offsets xml_i="14611" xml_f="14617" txt_i="7484" txt_f="7490">• 1-RM</offsets><break></break><offsets xml_i="14632" xml_f="14659" txt_i="7490" txt_f="7517">• Abdominal obesity and BMI</offsets></td><td></td></tr></tbody></table><table-wrap-foot><p><offsets xml_i="14714" xml_f="15013" txt_i="7519" txt_f="7818">ABPM, ambulatory blood pressure monitoring; AT, aerobic training; RT, resistance training; CT, concurrent training; HDL, high-density cholesterol; LDL, low-density cholesterol; RBC red blood cell; ESR, erythrocyte sedimentation rate; 1-RM, one-repetition maximum strength test; BMI, body mass index.</offsets></p></table-wrap-foot></table-wrap></p></sec><sec id="Sec2"><title><offsets xml_i="15080" xml_f="15094" txt_i="7821" txt_f="7835">Methods/design</offsets></title><p><offsets xml_i="15105" xml_f="15322" txt_i="7836" txt_f="8053">The study will be coordinated at the Fundação Universitária de Cardiologia (FUC) Health Sciences Graduate Program together with the Instituto de Cardiologia (IC) in the city of Porto Alegre, Rio Grande do Sul, Brazil.</offsets></p><sec id="Sec3"><title><offsets xml_i="15348" xml_f="15360" txt_i="8054" txt_f="8066">Study design</offsets></title><p><offsets xml_i="15371" xml_f="15467" txt_i="8067" txt_f="8163">A randomized controlled and evaluator-blinded clinical trial will be conducted as shown in Fig. </offsets><xref rid="Fig1" ref-type="fig"><offsets xml_i="15499" xml_f="15500" txt_i="8163" txt_f="8164">1</offsets></xref><offsets xml_i="15507" xml_f="15508" txt_i="8164" txt_f="8165">.</offsets><fig id="Fig1"><label><offsets xml_i="15530" xml_f="15536" txt_i="8165" txt_f="8171">Fig. 1</offsets></label><caption><p><offsets xml_i="15556" xml_f="15624" txt_i="8171" txt_f="8239">Study design. Flow chart of how the clinical trial will be conducted</offsets></p></caption><graphic xlink:href="13063_2016_1210_Fig1_HTML" id="MO1"></graphic></fig></p></sec><sec id="Sec4"><title><offsets xml_i="15743" xml_f="15759" txt_i="8242" txt_f="8258">Sample selection</offsets></title><p><offsets xml_i="15770" xml_f="16052" txt_i="8259" txt_f="8541">The study sample will comprise individuals with no history of cardiovascular disease (except for SAH controlled with the use of medications), neuromuscular, endocrine, and/or metabolic conditions (except for diabetes mellitus type 2) who are attending the IC health care facilities.</offsets></p><p><offsets xml_i="16059" xml_f="16558" txt_i="8542" txt_f="9041">Subjects will be selected based on information collected from their medical records. Eligible individuals will be contacted by telephone and informed of the purpose and procedures of the study. For those willing to participate, a first visit will be scheduled when a clinical questionnaire will be administered, and they will be asked to sign a free informed consent form to participate in the study. Other study visits will be scheduled for those meeting the inclusion criteria of the study (Table </offsets><xref rid="Tab3" ref-type="table"><offsets xml_i="16592" xml_f="16593" txt_i="9041" txt_f="9042">3</offsets></xref><offsets xml_i="16600" xml_f="16602" txt_i="9042" txt_f="9044">).</offsets><table-wrap id="Tab3"><label><offsets xml_i="16631" xml_f="16638" txt_i="9044" txt_f="9051">Table 3</offsets></label><caption><p><offsets xml_i="16658" xml_f="16704" txt_i="9051" txt_f="9097">Inclusion and exclusion criteria for the study</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><th><offsets xml_i="16770" xml_f="16788" txt_i="9098" txt_f="9116">Inclusion criteria</offsets></th><th><offsets xml_i="16797" xml_f="16815" txt_i="9116" txt_f="9134">Exclusion criteria</offsets></th></tr></thead><tbody><tr><td><offsets xml_i="16848" xml_f="16887" txt_i="9134" txt_f="9173">• Males and females aged 18 to 70 years</offsets><break></break><offsets xml_i="16902" xml_f="16922" txt_i="9173" txt_f="9193">• Diagnosed with SAH</offsets><break></break><offsets xml_i="16937" xml_f="16974" txt_i="9193" txt_f="9230">• Signed a free informed consent form</offsets><break></break><offsets xml_i="16989" xml_f="17030" txt_i="9230" txt_f="9271">• Considered insufficiently active (IPAQ)</offsets><break></break><offsets xml_i="17045" xml_f="17065" txt_i="9271" txt_f="9291">• Non-active smokers</offsets></td><td><offsets xml_i="17074" xml_f="17138" txt_i="9292" txt_f="9356">• Currently engaging in any type of systematic physical activity</offsets><break></break><offsets xml_i="17153" xml_f="17269" txt_i="9356" txt_f="9466">• Blood pressure hyper-reactivity in the clinical assessment (SBP &gt; 220 mmHg and/or increase in DBP &gt; 15 mmHg)</offsets><break></break><offsets xml_i="17284" xml_f="17313" txt_i="9466" txt_f="9495">• Ongoing infectious diseases</offsets><break></break><offsets xml_i="17328" xml_f="17359" txt_i="9495" txt_f="9526">• Obesity class II or III (BMI)</offsets><break></break><offsets xml_i="17374" xml_f="17541" txt_i="9526" txt_f="9690">• Heart failure class III or IV; recent cardiovascular event (in the last three months); chronic renal failure; and malignant disease with life expectancy &lt; 2 years</offsets><break></break><offsets xml_i="17556" xml_f="17650" txt_i="9690" txt_f="9784">• Orthopedic impairments or any physical or mental limitations that prevent physical exercises</offsets><break></break><offsets xml_i="17665" xml_f="17932" txt_i="9784" txt_f="10045">• After the training intervention, individuals who attended &lt; 85 % or missed &gt; 2 consecutive training sessions will be excluded from the sample. Subjects will be encouraged to complete any missed session at the end of training by performing additional sessions.</offsets></td></tr></tbody></table><table-wrap-foot><p><offsets xml_i="17978" xml_f="18149" txt_i="10046" txt_f="10217">SAH, systemic arterial hypertension; IPAQ, International Physical Activity Questionnaire; SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body mass index</offsets></p></table-wrap-foot></table-wrap></p><p><offsets xml_i="18191" xml_f="18263" txt_i="10219" txt_f="10291">The following formula will be used for the calculation of sample size (n</offsets><sub><offsets xml_i="18268" xml_f="18269" txt_i="10291" txt_f="10292">p</offsets></sub><offsets xml_i="18275" xml_f="18356" txt_i="10292" txt_f="10373">) to estimate the number of hypertensive individuals to be included in the study:</offsets><disp-formula id="Equa"><alternatives><tex-math id="M1"><offsets xml_i="18412" xml_f="18928" txt_i="10373" txt_f="10889">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$ \left({\upmu}_{\mathrm{p}}\right):\ {\mathrm{n}}_{\mathrm{p}0} = {\mathrm{s}}^2/\ {\left({\upmu}_{\mathrm{p}}\hbox{-}\ {\mathrm{x}}_{\mathrm{p}}\right)}^2\mathrm{x}\ {\left({\mathrm{t}}_{\upalpha; \mathrm{g}\mathrm{l}}\right)}^2, $$\end{document}</offsets></tex-math><mml:math id="M2"><mml:mfenced close=")" open="("><mml:msub><mml:mi mathvariant="normal"><offsets xml_i="19028" xml_f="19029" txt_i="10889" txt_f="10890">μ</offsets></mml:mi><mml:mi mathvariant="normal"><offsets xml_i="19067" xml_f="19068" txt_i="10890" txt_f="10891">p</offsets></mml:mi></mml:msub></mml:mfenced><mml:mo><offsets xml_i="19110" xml_f="19111" txt_i="10891" txt_f="10892">:</offsets></mml:mo><mml:mspace width="0.25em"></mml:mspace><mml:msub><mml:mi mathvariant="normal"><offsets xml_i="19199" xml_f="19200" txt_i="10892" txt_f="10893">n</offsets></mml:mi><mml:mrow><mml:mi mathvariant="normal"><offsets xml_i="19248" xml_f="19249" txt_i="10893" txt_f="10894">p</offsets></mml:mi><mml:mn><offsets xml_i="19266" xml_f="19267" txt_i="10894" txt_f="10895">0</offsets></mml:mn></mml:mrow></mml:msub><mml:mspace width="0.25em"></mml:mspace><mml:mo><offsets xml_i="19346" xml_f="19347" txt_i="10895" txt_f="10896">=</offsets></mml:mo><mml:mspace width="0.25em"></mml:mspace><mml:msup><mml:mi mathvariant="normal"><offsets xml_i="19435" xml_f="19436" txt_i="10896" txt_f="10897">s</offsets></mml:mi><mml:mn><offsets xml_i="19453" xml_f="19454" txt_i="10897" txt_f="10898">2</offsets></mml:mn></mml:msup><mml:mo stretchy="true"><offsets xml_i="19498" xml_f="19499" txt_i="10898" txt_f="10899">/</offsets></mml:mo><mml:mspace width="0.25em"></mml:mspace><mml:msup><mml:mfenced close=")" open="("><mml:mrow><mml:msub><mml:mi mathvariant="normal"><offsets xml_i="19639" xml_f="19640" txt_i="10899" txt_f="10900">μ</offsets></mml:mi><mml:mi mathvariant="normal"><offsets xml_i="19678" xml_f="19679" txt_i="10900" txt_f="10901">p</offsets></mml:mi></mml:msub><mml:mo><offsets xml_i="19707" xml_f="19708" txt_i="10901" txt_f="10902">‐</offsets></mml:mo><mml:mspace width="0.25em"></mml:mspace><mml:msub><mml:mi mathvariant="normal"><offsets xml_i="19796" xml_f="19797" txt_i="10902" txt_f="10903">x</offsets></mml:mi><mml:mi mathvariant="normal"><offsets xml_i="19835" xml_f="19836" txt_i="10903" txt_f="10904">p</offsets></mml:mi></mml:msub></mml:mrow></mml:mfenced><mml:mn><offsets xml_i="19889" xml_f="19890" txt_i="10904" txt_f="10905">2</offsets></mml:mn></mml:msup><mml:mi mathvariant="normal"><offsets xml_i="19939" xml_f="19940" txt_i="10905" txt_f="10906">x</offsets></mml:mi><mml:mspace width="0.25em"></mml:mspace><mml:msup><mml:mfenced close=")" open="("><mml:msub><mml:mi mathvariant="normal"><offsets xml_i="20070" xml_f="20071" txt_i="10906" txt_f="10907">t</offsets></mml:mi><mml:mrow><mml:mi mathvariant="normal"><offsets xml_i="20119" xml_f="20120" txt_i="10907" txt_f="10908">α</offsets></mml:mi><mml:mo><offsets xml_i="20137" xml_f="20138" txt_i="10908" txt_f="10909">;</offsets></mml:mo><mml:mi mathvariant="normal"><offsets xml_i="20176" xml_f="20177" txt_i="10909" txt_f="10910">g</offsets></mml:mi><mml:mi mathvariant="normal"><offsets xml_i="20215" xml_f="20216" txt_i="10910" txt_f="10911">l</offsets></mml:mi></mml:mrow></mml:msub></mml:mfenced><mml:mn><offsets xml_i="20269" xml_f="20270" txt_i="10911" txt_f="10912">2</offsets></mml:mn></mml:msup><mml:mtext><offsets xml_i="20301" xml_f="20302" txt_i="10912" txt_f="10913">,</offsets></mml:mtext></mml:math><graphic xlink:href="13063_2016_1210_Article_Equa.gif" position="anchor"></graphic></alternatives></disp-formula></p><p><offsets xml_i="20445" xml_f="20453" txt_i="10914" txt_f="10922">where, n</offsets><sub><offsets xml_i="20458" xml_f="20460" txt_i="10922" txt_f="10924">po</offsets></sub><offsets xml_i="20466" xml_f="20502" txt_i="10924" txt_f="10960"> = sample size at time point zero, s</offsets><sup><offsets xml_i="20507" xml_f="20508" txt_i="10960" txt_f="10961">2</offsets></sup><offsets xml_i="20514" xml_f="20561" txt_i="10961" txt_f="11008"> = variance of the sampling distribution, and t</offsets><sub><offsets xml_i="20566" xml_f="20570" txt_i="11008" txt_f="11012">α;gl</offsets></sub><offsets xml_i="20576" xml_f="20649" txt_i="11012" txt_f="11085"> = sampling distribution according to a predetermined error probability (</offsets><italic><offsets xml_i="20657" xml_f="20658" txt_i="11085" txt_f="11086">P</offsets></italic><offsets xml_i="20667" xml_f="20704" txt_i="11086" txt_f="11123"> ≤ 0.05) and degrees of freedom for n</offsets><sub><offsets xml_i="20709" xml_f="20711" txt_i="11123" txt_f="11125">po</offsets></sub><offsets xml_i="20717" xml_f="20718" txt_i="11125" txt_f="11126">.</offsets></p><p><offsets xml_i="20725" xml_f="20793" txt_i="11127" txt_f="11195">The mean incidence rate of SAH in Brazil is 20 % of the population [</offsets><xref ref-type="bibr" rid="CR40"><offsets xml_i="20826" xml_f="20828" txt_i="11195" txt_f="11197">40</offsets></xref><offsets xml_i="20835" xml_f="20871" txt_i="11197" txt_f="11233">]. Considering the baseline value (n</offsets><sub><offsets xml_i="20876" xml_f="20877" txt_i="11233" txt_f="11234">0</offsets></sub><offsets xml_i="20883" xml_f="20892" txt_i="11234" txt_f="11243"> = 30); t</offsets><sub><offsets xml_i="20897" xml_f="20901" txt_i="11243" txt_f="11247">α;gl</offsets></sub><offsets xml_i="20907" xml_f="20911" txt_i="11247" txt_f="11251"> = t</offsets><sub><offsets xml_i="20916" xml_f="20923" txt_i="11251" txt_f="11258">0.05;29</offsets></sub><offsets xml_i="20929" xml_f="20940" txt_i="11258" txt_f="11269"> = 2.045; s</offsets><sup><offsets xml_i="20945" xml_f="20946" txt_i="11269" txt_f="11270">2</offsets></sup><offsets xml_i="20952" xml_f="21178" txt_i="11270" txt_f="11496"> = 0.05 (based on the maximum value of the coefficient of variation of endothelial vasodilation); and the maximum error of the estimate taken as the maximum variability in arterial diameter measures by two observers (0.02 %) [</offsets><xref ref-type="bibr" rid="CR41"><offsets xml_i="21211" xml_f="21213" txt_i="11496" txt_f="11498">41</offsets></xref><offsets xml_i="21220" xml_f="21246" txt_i="11498" txt_f="11524">], it was estimated that n</offsets><sub><offsets xml_i="21251" xml_f="21253" txt_i="11524" txt_f="11526">p1</offsets></sub><offsets xml_i="21259" xml_f="21323" txt_i="11526" txt_f="11590"> = 26.1 ≅ 26 hypertensive individuals. Thus, in the estimate of </offsets><italic><offsets xml_i="21331" xml_f="21333" txt_i="11590" txt_f="11592">n,</offsets></italic><offsets xml_i="21342" xml_f="21378" txt_i="11592" txt_f="11628"> the approximation used considered n</offsets><sub><offsets xml_i="21383" xml_f="21385" txt_i="11628" txt_f="11630">p1</offsets></sub><offsets xml_i="21391" xml_f="21412" txt_i="11630" txt_f="11651"> = 26, gl = 23, and t</offsets><sub><offsets xml_i="21417" xml_f="21424" txt_i="11651" txt_f="11658">0.05;23</offsets></sub><offsets xml_i="21430" xml_f="21445" txt_i="11658" txt_f="11673"> = 2.069. The n</offsets><sub><offsets xml_i="21450" xml_f="21452" txt_i="11673" txt_f="11675">p1</offsets></sub><offsets xml_i="21458" xml_f="21522" txt_i="11675" txt_f="11739"> = 26.8 ≅ 27. The estimate of the sample size for the study was </offsets><italic><offsets xml_i="21530" xml_f="21531" txt_i="11739" txt_f="11740">n</offsets></italic><offsets xml_i="21540" xml_f="21644" txt_i="11740" txt_f="11844"> = 80.3 ≅ 81 hypertensive individuals who will be randomly assigned to the three training interventions.</offsets></p></sec><sec id="Sec5"><title><offsets xml_i="21676" xml_f="21699" txt_i="11846" txt_f="11869">Randomization procedure</offsets></title><p><offsets xml_i="21710" xml_f="21798" txt_i="11870" txt_f="11958">A randomization for the proposed interventions will be generated by a computer program (</offsets><ext-link ext-link-type="uri" xlink:href="http://www.randomization.org/"><offsets xml_i="21871" xml_f="21892" txt_i="11958" txt_f="11979">www.randomization.org</offsets></ext-link><offsets xml_i="21903" xml_f="22432" txt_i="11979" txt_f="12508">) including the distribution coded at a 1:1 ratio. The random assignment of subjects to training intervention groups will be into three blocks of 27. Subjects will be drawn up to 27 in each intervention group: aerobic training (AT), resistance training (RT), and combined training (CT, resistance and aerobic). All subjects will be blinded to intervention allocation and will have access to this information only after the baseline assessment. All evaluators of the study subjects will be also blinded to intervention allocation.</offsets></p></sec><sec id="Sec6"><title><offsets xml_i="22464" xml_f="22495" txt_i="12510" txt_f="12541">Baseline assessment of subjects</offsets></title><p><offsets xml_i="22506" xml_f="22961" txt_i="12542" txt_f="12997">After recruitment, the subjects will undergo baseline assessment to collect information on their main characteristics before intervention. A descriptive exploratory questionnaire will be administered to collect information on i) demographic and socioeconomic variables (gender, age, socioeconomic status, education, skin color and marital status); ii) behavioral variables (physical activity measured by the International Physical Activity Questionnaire (</offsets><ext-link ext-link-type="uri" xlink:href="http://www.ipaq.ki.se/"><offsets xml_i="23027" xml_f="23041" txt_i="12997" txt_f="13011">www.ipaq.ki.se</offsets></ext-link><offsets xml_i="23052" xml_f="23347" txt_i="13011" txt_f="13306">), smoking status, and alcohol consumption); iii) anthropometric variables (body weight, height, and waist circumference); iv) clinical variables (BP and use of antihypertensive medication); and v) quality of life assessed by the Medical Outcomes Study 36-Item Short Form Health Survey (SF-36) [</offsets><xref ref-type="bibr" rid="CR42"><offsets xml_i="23380" xml_f="23382" txt_i="13306" txt_f="13308">42</offsets></xref><offsets xml_i="23389" xml_f="23889" txt_i="13308" txt_f="13808">]. Eligible individuals who are willing to participate will be instructed to fast for 8 h and come for a scheduled second visit at the study site. In this visit, subjects will have blood samples collected for blood testing, in addition to the assessment of FMD of the brachial artery and ambulatory blood pressure monitoring (ABPM) cuff placement. A snack will be offered at the end of this visit. In the third visit, the ABPM cuff will be removed and subjects will undergo physical fitness tests (VO</offsets><sub><offsets xml_i="23894" xml_f="23895" txt_i="13808" txt_f="13809">2</offsets></sub><offsets xml_i="23901" xml_f="24194" txt_i="13809" txt_f="14102">max). In the fourth visit, 1-RM testing will be conducted. Subjects who did not show up for the scheduled visits will be contacted again. All blood samples will be collected by a nurse technician. All assessment procedures will be supervised by the study investigators and ICFUC medical staff.</offsets></p></sec><sec id="Sec7"><title><offsets xml_i="24226" xml_f="24237" txt_i="14104" txt_f="14115">Assessments</offsets></title><sec id="Sec8"><title><offsets xml_i="24267" xml_f="24283" txt_i="14116" txt_f="14132">Blood collection</offsets></title><p><offsets xml_i="24294" xml_f="24857" txt_i="14133" txt_f="14696">Blood collection and testing will be performed at the ICFUC. Subjects’ blood will be collected after a fast of 8 h. The blood sample will be tested for biochemical screening (lipid profile, glucose, glycated hemoglobin, and creatinine), number of EPCs and number of circulating endothelial microparticles. In addition, blood rheology will be assessed for potential changes in the sample studied including increased blood viscosity, reduced red blood cell (RBC) deformability, increased RBC aggregation, fibrinogen levels, and erythrocyte sedimentation rate (ESR).</offsets></p></sec></sec><sec id="Sec9"><title><offsets xml_i="24895" xml_f="24948" txt_i="14699" txt_f="14752">Progenitor cell and endothelial progenitor cell count</offsets></title><p><offsets xml_i="24959" xml_f="26293" txt_i="14753" txt_f="16087">A 15-ml blood sample for the EPCs will be collected in a Sodium Heparin Vacutainer™ tube. Peripheral blood mononuclear cells (PBMC) will be isolated using Ficoll-Paque (GE Heathcare Life Sciences, Uppsala, Sweden). Progenitor cells (PCs) will be defined as CD34+/CD45dim, and EPCs as CD34+/KDR+/CD45dim. Briefly, blood samples will be diluted once with phosphate buffered saline (PBS) and layered onto Ficoll-Paque in 15-ml conical tubes (BD Biosciences, San Jose, CA, USA). Each tube will be centrifuged at 400 xg for 30 min (Eppendorf-5810, Hamburg, Germany), and the PBMCs at the interface will be collected. Cells will be washed once with RPMI-1640 medium (Gibco™, Vancouver, Canada); stained with 5 μl of antihuman-CD45 FITC, 5 μl of antihuman-CD34 PE (clone 6G12), and 8 ul of antihuman-KDR-Alexa Fluor 647 (BD Biosciences, San Jose CA, USA); and incubated in the dark for 30 min, followed by the addition of 500 μl of PBS until resuspension and acquisition in a flow cytometer (FACSCalibur, CellQuest software, BD Biosciences, San Diego, CA, USA). The total number of events recorded on the mononuclear cells gate was 200,000. The percentage of CD34+ cells was calculated based on the measured number of leukocytes (CD45+ cells) using the ISHAGE (International Society for Hematotherapy and Graft Engineering) gating strategy [</offsets><xref ref-type="bibr" rid="CR43"><offsets xml_i="26326" xml_f="26328" txt_i="16087" txt_f="16089">43</offsets></xref><offsets xml_i="26335" xml_f="26337" txt_i="16089" txt_f="16091">].</offsets></p></sec><sec id="Sec10"><title><offsets xml_i="26370" xml_f="26414" txt_i="16093" txt_f="16137">Circulating endothelial microparticles count</offsets></title><p><offsets xml_i="26425" xml_f="27433" txt_i="16138" txt_f="17140">A 5-ml blood sample for circulating endothelial microparticles will be collected in a Citrate Vacutainer™ tube. These samples will be analyzed for CD31+/CD41- and CD144+. Initially, the blood will be rendered to separate the platelet-rich plasma and the platelet-poor plasma. All blood samples will be subjected to a two-step protocol centrifugation (860 xg for 15 min at 4 °C, followed by 1700 xg for 5 min at 20 °C) before being stored at -80 °C. Phenotype analysis of the endothelial microparticles will be subsequently performed on samples thawed using a flow cytometer Fluorescence Activated Cell Analyser (FACScanto II da BD Biosciences, San Jose, CA, USA) and the results analyzed with the BD FACS Diva software (BD). For phenotyping of the endothelial microparticles, the following antibodies will be used: anti-CD31+ PE, anti-CD41+ PC7, and anti-CD144+ PE. Endothelial microparticles will be defined as elements with size &gt; 0.1 and &lt; 1.0 μm and showing surface markers CD31+/CD41- and CD144+ [</offsets><xref ref-type="bibr" rid="CR44"><offsets xml_i="27466" xml_f="27468" txt_i="17140" txt_f="17142">44</offsets></xref><offsets xml_i="27475" xml_f="27477" txt_i="17142" txt_f="17144">].</offsets></p></sec><sec id="Sec11"><title><offsets xml_i="27510" xml_f="27552" txt_i="17146" txt_f="17188">Assessment of flow-mediated dilation (FMD)</offsets></title><p><offsets xml_i="27563" xml_f="28627" txt_i="17189" txt_f="18253">Endothelial function will be measured noninvasively by using brachial artery ultrasound (EnVisor series, Philips Ultrasound, Bothell, WA, USA). This assessment will be performed with a 7 to 12 MHz linear transducer in a heated room at 21 to 24 °C at ICFUC. A software program will be used for two-dimensional color-Doppler imaging acquisition with a simultaneously recorded electrocardiogram (ECG). Image data will be recorded on a DVD. To minimize operational errors, the subject’s arm, and the ultrasound transducer will be positioned and maintained in the same position during the procedure. Baseline images will be recorded. A cuff will be placed around the forearm and inflated to 50 mmHg above systolic pressure for at least 5 min and then removed. Longitudinal ultrasound images of the brachial artery walls will be acquired to assess endothelium-dependent vasodilation. The expected coefficient of variation between the images will be 1.8 to 5.0 %. Flow-dependent vasodilation responses will be expressed as the percentage change in the brachial diameter [</offsets><xref ref-type="bibr" rid="CR36"><offsets xml_i="28660" xml_f="28662" txt_i="18253" txt_f="18255">36</offsets></xref><offsets xml_i="28669" xml_f="28671" txt_i="18255" txt_f="18257">].</offsets></p></sec><sec id="Sec12"><title><offsets xml_i="28704" xml_f="28720" txt_i="18259" txt_f="18275">Echocardiography</offsets></title><p><offsets xml_i="28731" xml_f="29443" txt_i="18276" txt_f="18988">Echocardiography is a noninvasive imaging approach that uses ultrasound to assess the structures and functioning of the heart; it measures the chamber size and mobility of the walls, valve structures, ejection fraction, diastolic dysfunction parameters, and the direction and speed of blood flowing through the heart chambers. Medical personnel at ICFUC accredited by the Brazilian Society of Echocardiography and blinded to intervention allocation will perform transthoracic echocardiograms with image acquisition in second-harmonic generation with the use of ACUSON SC2000 equipment and a 3 to 12 MHz transducer (Siemens). This data will be digitally stored for further analysis by more experienced evaluators.</offsets></p></sec><sec id="Sec13"><title><offsets xml_i="29476" xml_f="29490" txt_i="18990" txt_f="19004">Blood pressure</offsets></title><p><offsets xml_i="29501" xml_f="30573" txt_i="19005" txt_f="20077">Two different approaches will be used to evaluate the BP levels: clinical assessment and ambulatory blood pressure monitoring (AMBP). The clinical assessment will consist of acute and subacute BP measurements as a way to evaluate exercise responses. Measurements will be taken with the subject in a sitting position using a semi-automatic sphygmomanometer (Omron 705CP). BP levels will be measured in both arms in the pre-study assessments, and the arm with highest values will be used for measurements in the study. Subacute clinical assessments will be conducted at the following time points: before the beginning of each training session (pre-exercise), immediately after exercise (early post-exercise), and 20 min after the end of each session (late post-exercise). ABPM will be performed in all study groups before the first exercise session and at the completion of the entire training intervention. Blood pressure measurements will be obtained from an oscillometric Dina-map™ device. Both assessments will follow the VI Brazilian National Guidelines in Cardiology [</offsets><xref ref-type="bibr" rid="CR40"><offsets xml_i="30606" xml_f="30608" txt_i="20077" txt_f="20079">40</offsets></xref><offsets xml_i="30615" xml_f="30617" txt_i="20079" txt_f="20081">].</offsets></p></sec><sec id="Sec14"><title><offsets xml_i="30650" xml_f="30669" txt_i="20083" txt_f="20102">Functional capacity</offsets></title><p><offsets xml_i="30680" xml_f="30682" txt_i="20103" txt_f="20105">VO</offsets><sub><offsets xml_i="30687" xml_f="30688" txt_i="20105" txt_f="20106">2</offsets></sub><offsets xml_i="30694" xml_f="31560" txt_i="20106" txt_f="20972">max will be obtained from a cardiopulmonary exercise test using a cycle ergometer and 12-lead ECG monitoring supervised by a cardiologist. Gas exchange measurements will be taken with the use of an ergo spirometer (VO2000 model, Inbramed, Porto Alegre, Brazil). This device collects exhaled gas samples and can store data acquired with each breath (breath-by-breath). Heart rate will be monitored with a frequency meter (Polar S610 model) as follows: online heart rate readings, determination of maximum heart rate at each exercise stage, and stopwatch with partial times. The maximal exercise test will be scheduled at least 48 h in advance. Upon participant arrival at the study site, BP levels will be measured according to the study protocol. Subjects will be asked to sit on a chair, and a facemask (or nozzle) and a frequency meter will be attached. Resting VO</offsets><sub><offsets xml_i="31565" xml_f="31566" txt_i="20972" txt_f="20973">2</offsets></sub><offsets xml_i="31572" xml_f="31580" txt_i="20973" txt_f="20981"> and VCO</offsets><sub><offsets xml_i="31585" xml_f="31586" txt_i="20981" txt_f="20982">2</offsets></sub><xref ref-type="bibr" rid="CR45"><offsets xml_i="31625" xml_f="31627" txt_i="20982" txt_f="20984">45</offsets></xref><offsets xml_i="31634" xml_f="31636" txt_i="20984" txt_f="20986">].</offsets></p></sec><sec id="Sec15"><title><offsets xml_i="31669" xml_f="31718" txt_i="20988" txt_f="21037">One-repetition maximum strength (1-RM) assessment</offsets></title><p><offsets xml_i="31729" xml_f="32223" txt_i="21038" txt_f="21532">The one-repetition maximum strength test (1-RM) will be used to measure the maximum strength. Subjects will warm up on a cycle ergometer for 5 min. They will then be instructed to perform the maximum number of repetitions with a given load until they can perform only one lift of a load in up to five attempts to achieve the maximum load. A rest period of 3 to 5 min will be provided between each attempt, so rest intervals are of sufficient length to allow the restoration of energy reserves [</offsets><xref ref-type="bibr" rid="CR46"><offsets xml_i="32256" xml_f="32258" txt_i="21532" txt_f="21534">46</offsets></xref><offsets xml_i="32265" xml_f="32873" txt_i="21534" txt_f="22142">]. The same procedure will be followed for all types of strength exercises proposed in the study (leg press, bench press, knee extension, biceps curl, knee bend, and low row). The speed of movements will be controlled with a metronome in both intervention protocols. Exercises will be performed at a pace of 2 seconds for both concentric and eccentric phases. This test will take place at three time points: during the first 2 weeks (60 % of 1-RM); during the intermediate weeks (70 % of 1-RM); and at the end of week 8 (80 % of 1-RM) to maintain exercise at an appropriate intensity throughout the protocol.</offsets></p></sec><sec id="Sec16"><title><offsets xml_i="32906" xml_f="32928" txt_i="22144" txt_f="22166">Intervention protocols</offsets></title><p><offsets xml_i="32939" xml_f="33222" txt_i="22167" txt_f="22450">The study intervention will comprise 12 weeks of exercise sessions, lasting on average 50 min, three times a week. Exercise sessions will include a warm-up period of 5 to 10 min at the beginning, resistance or combined aerobic exercises for 40 min, and a cool down/relaxation period.</offsets></p><p><offsets xml_i="33229" xml_f="33359" txt_i="22451" txt_f="22581">AT will be performed on a cycle ergometer for the entire intervention. Subjects will be monitored with heart rate monitors (Table </offsets><xref rid="Tab4" ref-type="table"><offsets xml_i="33393" xml_f="33394" txt_i="22581" txt_f="22582">4</offsets></xref><offsets xml_i="33401" xml_f="33403" txt_i="22582" txt_f="22584">).</offsets><table-wrap id="Tab4"><label><offsets xml_i="33432" xml_f="33439" txt_i="22584" txt_f="22591">Table 4</offsets></label><caption><p><offsets xml_i="33459" xml_f="33552" txt_i="22591" txt_f="22684">Intensity and duration of aerobic training on a stationary bike during a 12-week intervention</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><th></th><th><offsets xml_i="33627" xml_f="33634" txt_i="22685" txt_f="22692">Phase I</offsets></th><th><offsets xml_i="33643" xml_f="33651" txt_i="22692" txt_f="22700">Phase II</offsets></th><th><offsets xml_i="33660" xml_f="33669" txt_i="22700" txt_f="22709">Phase III</offsets></th></tr></thead><tbody><tr><td><offsets xml_i="33702" xml_f="33711" txt_i="22709" txt_f="22718">Intensity</offsets></td><td><offsets xml_i="33720" xml_f="33734" txt_i="22719" txt_f="22733">50 to 65 % HRR</offsets></td><td><offsets xml_i="33743" xml_f="33757" txt_i="22734" txt_f="22748">55 to 70 % HRR</offsets></td><td><offsets xml_i="33766" xml_f="33780" txt_i="22749" txt_f="22763">60 to 75 % HRR</offsets></td></tr><tr><td><offsets xml_i="33798" xml_f="33814" txt_i="22764" txt_f="22780">Session duration</offsets></td><td><offsets xml_i="33823" xml_f="33829" txt_i="22781" txt_f="22787">40 min</offsets></td><td><offsets xml_i="33838" xml_f="33844" txt_i="22788" txt_f="22794">40 min</offsets></td><td><offsets xml_i="33853" xml_f="33859" txt_i="22795" txt_f="22801">40 min</offsets></td></tr><tr><td><offsets xml_i="33877" xml_f="33902" txt_i="22802" txt_f="22827">Exercise duration (weeks)</offsets></td><td><offsets xml_i="33911" xml_f="33912" txt_i="22828" txt_f="22829">4</offsets></td><td><offsets xml_i="33921" xml_f="33922" txt_i="22830" txt_f="22831">4</offsets></td><td><offsets xml_i="33931" xml_f="33932" txt_i="22832" txt_f="22833">4</offsets></td></tr></tbody></table><table-wrap-foot><p><offsets xml_i="33978" xml_f="34001" txt_i="22834" txt_f="22857">HRR, heart rate reserve</offsets></p></table-wrap-foot></table-wrap></p><p><offsets xml_i="34043" xml_f="34257" txt_i="22859" txt_f="23073">RT will include six types of exercises that alternate between large and small muscle groups (leg press, bench press, knee extension, biceps curl, knee bend, and low row) for the entire training intervention (Table </offsets><xref rid="Tab5" ref-type="table"><offsets xml_i="34291" xml_f="34292" txt_i="23073" txt_f="23074">5</offsets></xref><offsets xml_i="34299" xml_f="34301" txt_i="23074" txt_f="23076">).</offsets><table-wrap id="Tab5"><label><offsets xml_i="34330" xml_f="34337" txt_i="23076" txt_f="23083">Table 5</offsets></label><caption><p><offsets xml_i="34357" xml_f="34496" txt_i="23083" txt_f="23222">Intensity, number of sets, repetitions, rest period between sets, and session duration of resistance training during a 12-week intervention</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><th></th><th><offsets xml_i="34571" xml_f="34578" txt_i="23223" txt_f="23230">Phase I</offsets></th><th><offsets xml_i="34587" xml_f="34595" txt_i="23230" txt_f="23238">Phase II</offsets></th><th><offsets xml_i="34604" xml_f="34613" txt_i="23238" txt_f="23247">Phase III</offsets></th></tr></thead><tbody><tr><td><offsets xml_i="34646" xml_f="34655" txt_i="23247" txt_f="23256">Intensity</offsets></td><td><offsets xml_i="34664" xml_f="34673" txt_i="23257" txt_f="23266">60 % 1-RM</offsets></td><td><offsets xml_i="34682" xml_f="34691" txt_i="23267" txt_f="23276">70 % 1-RM</offsets></td><td><offsets xml_i="34700" xml_f="34709" txt_i="23277" txt_f="23286">80 % 1-RM</offsets></td></tr><tr><td><offsets xml_i="34727" xml_f="34731" txt_i="23287" txt_f="23291">Sets</offsets></td><td><offsets xml_i="34740" xml_f="34741" txt_i="23292" txt_f="23293">4</offsets></td><td><offsets xml_i="34750" xml_f="34751" txt_i="23294" txt_f="23295">4</offsets></td><td><offsets xml_i="34760" xml_f="34761" txt_i="23296" txt_f="23297">4</offsets></td></tr><tr><td><offsets xml_i="34779" xml_f="34790" txt_i="23298" txt_f="23309">Repetitions</offsets></td><td><offsets xml_i="34799" xml_f="34807" txt_i="23310" txt_f="23318">10 to 12</offsets></td><td><offsets xml_i="34816" xml_f="34823" txt_i="23319" txt_f="23326">8 to 10</offsets></td><td><offsets xml_i="34832" xml_f="34838" txt_i="23327" txt_f="23333">6 to 8</offsets></td></tr><tr><td><offsets xml_i="34856" xml_f="34880" txt_i="23334" txt_f="23358">Rest period between sets</offsets></td><td><offsets xml_i="34889" xml_f="34893" txt_i="23359" txt_f="23363">60 s</offsets></td><td><offsets xml_i="34902" xml_f="34906" txt_i="23364" txt_f="23368">60 s</offsets></td><td><offsets xml_i="34915" xml_f="34919" txt_i="23369" txt_f="23373">90 s</offsets></td></tr><tr><td><offsets xml_i="34937" xml_f="34953" txt_i="23374" txt_f="23390">Session duration</offsets></td><td><offsets xml_i="34962" xml_f="34968" txt_i="23391" txt_f="23397">40 min</offsets></td><td><offsets xml_i="34977" xml_f="34983" txt_i="23398" txt_f="23404">40 min</offsets></td><td><offsets xml_i="34992" xml_f="34998" txt_i="23405" txt_f="23411">40 min</offsets></td></tr><tr><td><offsets xml_i="35016" xml_f="35041" txt_i="23412" txt_f="23437">Exercise duration (weeks)</offsets></td><td><offsets xml_i="35050" xml_f="35051" txt_i="23438" txt_f="23439">4</offsets></td><td><offsets xml_i="35060" xml_f="35061" txt_i="23440" txt_f="23441">4</offsets></td><td><offsets xml_i="35070" xml_f="35071" txt_i="23442" txt_f="23443">4</offsets></td></tr></tbody></table><table-wrap-foot><p><offsets xml_i="35117" xml_f="35159" txt_i="23444" txt_f="23486">1-RM, one-repetition maximum strength test</offsets></p></table-wrap-foot></table-wrap></p><p><offsets xml_i="35201" xml_f="35444" txt_i="23488" txt_f="23731">CT will consist of resistance and aerobic exercises combined in one session performed over a 40-min period set as in the other two protocols, so that training volume is similar across all intervention groups for the entire intervention (Table </offsets><xref rid="Tab6" ref-type="table"><offsets xml_i="35478" xml_f="35479" txt_i="23731" txt_f="23732">6</offsets></xref><offsets xml_i="35486" xml_f="35488" txt_i="23732" txt_f="23734">).</offsets><table-wrap id="Tab6"><label><offsets xml_i="35517" xml_f="35524" txt_i="23734" txt_f="23741">Table 6</offsets></label><caption><p><offsets xml_i="35544" xml_f="35683" txt_i="23741" txt_f="23880">Intensity, number of sets, repetitions, rest period between sets, and session duration of concurrent training during a 12-week intervention</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><th></th><th><offsets xml_i="35758" xml_f="35765" txt_i="23881" txt_f="23888">Phase I</offsets></th><th><offsets xml_i="35774" xml_f="35782" txt_i="23888" txt_f="23896">Phase II</offsets></th><th><offsets xml_i="35791" xml_f="35800" txt_i="23896" txt_f="23905">Phase III</offsets></th></tr></thead><tbody><tr><td><offsets xml_i="35833" xml_f="35852" txt_i="23905" txt_f="23924">Resistance training</offsets></td><td></td><td></td><td></td></tr><tr><td><offsets xml_i="35897" xml_f="35907" txt_i="23928" txt_f="23938"> Intensity</offsets></td><td><offsets xml_i="35916" xml_f="35925" txt_i="23939" txt_f="23948">60 % 1-RM</offsets></td><td><offsets xml_i="35934" xml_f="35943" txt_i="23949" txt_f="23958">70 % 1-RM</offsets></td><td><offsets xml_i="35952" xml_f="35961" txt_i="23959" txt_f="23968">80 % 1-RM</offsets></td></tr><tr><td><offsets xml_i="35979" xml_f="35984" txt_i="23969" txt_f="23974"> Sets</offsets></td><td><offsets xml_i="35993" xml_f="35994" txt_i="23975" txt_f="23976">2</offsets></td><td><offsets xml_i="36003" xml_f="36004" txt_i="23977" txt_f="23978">2</offsets></td><td><offsets xml_i="36013" xml_f="36014" txt_i="23979" txt_f="23980">2</offsets></td></tr><tr><td><offsets xml_i="36032" xml_f="36044" txt_i="23981" txt_f="23993"> Repetitions</offsets></td><td><offsets xml_i="36053" xml_f="36061" txt_i="23994" txt_f="24002">10 to 12</offsets></td><td><offsets xml_i="36070" xml_f="36077" txt_i="24003" txt_f="24010">8 to 10</offsets></td><td><offsets xml_i="36086" xml_f="36092" txt_i="24011" txt_f="24017">6 to 8</offsets></td></tr><tr><td><offsets xml_i="36110" xml_f="36135" txt_i="24018" txt_f="24043"> Rest period between sets</offsets></td><td><offsets xml_i="36144" xml_f="36148" txt_i="24044" txt_f="24048">60 s</offsets></td><td><offsets xml_i="36157" xml_f="36161" txt_i="24049" txt_f="24053">60 s</offsets></td><td><offsets xml_i="36170" xml_f="36174" txt_i="24054" txt_f="24058">90 s</offsets></td></tr><tr><td><offsets xml_i="36192" xml_f="36209" txt_i="24059" txt_f="24076"> Session duration</offsets></td><td><offsets xml_i="36218" xml_f="36224" txt_i="24077" txt_f="24083">20 min</offsets></td><td><offsets xml_i="36233" xml_f="36239" txt_i="24084" txt_f="24090">20 min</offsets></td><td><offsets xml_i="36248" xml_f="36254" txt_i="24091" txt_f="24097">20 min</offsets></td></tr><tr><td><offsets xml_i="36272" xml_f="36288" txt_i="24098" txt_f="24114">Aerobic training</offsets></td><td></td><td></td><td></td></tr><tr><td><offsets xml_i="36333" xml_f="36343" txt_i="24118" txt_f="24128"> Intensity</offsets></td><td><offsets xml_i="36352" xml_f="36366" txt_i="24129" txt_f="24143">50 to 65 % HRR</offsets></td><td><offsets xml_i="36375" xml_f="36389" txt_i="24144" txt_f="24158">55 to 70 % HRR</offsets></td><td><offsets xml_i="36398" xml_f="36412" txt_i="24159" txt_f="24173">60 to 75 % HRR</offsets></td></tr><tr><td><offsets xml_i="36430" xml_f="36447" txt_i="24174" txt_f="24191"> Session duration</offsets></td><td><offsets xml_i="36456" xml_f="36462" txt_i="24192" txt_f="24198">20 min</offsets></td><td><offsets xml_i="36471" xml_f="36477" txt_i="24199" txt_f="24205">20 min</offsets></td><td><offsets xml_i="36486" xml_f="36492" txt_i="24206" txt_f="24212">20 min</offsets></td></tr><tr><td><offsets xml_i="36510" xml_f="36535" txt_i="24213" txt_f="24238">Exercise duration (weeks)</offsets></td><td><offsets xml_i="36544" xml_f="36545" txt_i="24239" txt_f="24240">4</offsets></td><td><offsets xml_i="36554" xml_f="36555" txt_i="24241" txt_f="24242">4</offsets></td><td><offsets xml_i="36564" xml_f="36565" txt_i="24243" txt_f="24244">4</offsets></td></tr></tbody></table><table-wrap-foot><p><offsets xml_i="36611" xml_f="36678" txt_i="24245" txt_f="24312">1-RM, one-repetition maximum strength test; HRR, heart rate reserve</offsets></p></table-wrap-foot></table-wrap></p><p><offsets xml_i="36720" xml_f="36924" txt_i="24314" txt_f="24518">A basic training principle is the progression of exercise intensity, duration, or frequency. Progression of exercise in the study intervention will be through gradual exertion increase for the protocols [</offsets><xref ref-type="bibr" rid="CR46"><offsets xml_i="36957" xml_f="36959" txt_i="24518" txt_f="24520">46</offsets></xref><offsets xml_i="36966" xml_f="37088" txt_i="24520" txt_f="24642">]. Borg’s rating scale of perceived exertion (6 to 20 point scale) will be used to help control the training intensities [</offsets><xref ref-type="bibr" rid="CR47"><offsets xml_i="37121" xml_f="37123" txt_i="24642" txt_f="24644">47</offsets></xref><offsets xml_i="37130" xml_f="37401" txt_i="24644" txt_f="24915">]. All subjects will be allowed an initial adjustment period. Those with resting BP levels higher than 160 mmHg (SBP) and/or 105 mmHg (DBP) before cardiopulmonary testing, 1-RM, or an exercise session (AT, RT and CT) will not be allowed to participate in any activities [</offsets><xref ref-type="bibr" rid="CR40"><offsets xml_i="37434" xml_f="37436" txt_i="24915" txt_f="24917">40</offsets></xref><offsets xml_i="37443" xml_f="37674" txt_i="24917" txt_f="25148">]. Those experiencing BP higher than the recommended level on a second occasion will be referred to the study cardiologist for evaluation. The cardiologist will determine whether the subject can continue participating in the study.</offsets></p><p><offsets xml_i="37681" xml_f="38798" txt_i="25149" txt_f="26266">Subjects diagnosed with SAH and diabetes mellitus type 2 will have their blood glucose checked (Optium Xceed, Abbott Diabetes Care, Inc., Alameda, CA, USA) in addition to BP measurements before cardiopulmonary exercise testing, 1-RM or an exercise session (AT, RT, and CT) and every 15 min throughout exercise sessions. If the blood glucose levels are lower than 100 mg/dL during cardiopulmonary exercise testing, 1-RM, or exercise sessions (AT, RT and CT), subjects will receive 30 to 45 g glucose gel (Gli-Instan, Lightsweet ™) to maintain levels above 120 mg/dL, and their blood glucose will be checked again 15 min later. Those with blood glucose higher than 250 mg/dL will have their urine tested for the presence of ketones (ComboStik™, Gyung-Nam, Korea), and they will be allowed to resume exercise only if test results are negative. Subjects with blood glucose lower than 100 mg/dL during exercise sessions will have to discontinue exercising and be offered a snack. Their blood glucose will be tested again 15 min later, and they will be allowed to resume exercise only if their test results are acceptable [</offsets><xref ref-type="bibr" rid="CR48"><offsets xml_i="38831" xml_f="38833" txt_i="26266" txt_f="26268">48</offsets></xref><offsets xml_i="38840" xml_f="38842" txt_i="26268" txt_f="26270">].</offsets></p></sec><sec id="Sec17"><title><offsets xml_i="38875" xml_f="38897" txt_i="26272" txt_f="26294">Statistical procedures</offsets></title><p><offsets xml_i="38908" xml_f="39047" txt_i="26295" txt_f="26434">For data comparison between pre-exercise and post-exercise and across groups, nonparametric (Spearman’s correlation (ρ), chi-square test (χ</offsets><sup><offsets xml_i="39052" xml_f="39053" txt_i="26434" txt_f="26435">2</offsets></sup><offsets xml_i="39059" xml_f="39320" txt_i="26435" txt_f="26696">), and Mann–Whitney U test), and parametric tests (t-test, analysis of variance (ANOVA), multivariate analysis of variance (MANOVA), multivariate linear regression, and canonical discriminant analysis) will be used depending on the variable studied, as well as </offsets><italic><offsets xml_i="39328" xml_f="39336" txt_i="26696" txt_f="26704">post hoc</offsets></italic><offsets xml_i="39345" xml_f="39399" txt_i="26704" txt_f="26758"> tests (Duncan and Waller-Duncan - ANOVA and MANOVA) [</offsets><xref ref-type="bibr" rid="CR49"><offsets xml_i="39432" xml_f="39434" txt_i="26758" txt_f="26760">49</offsets></xref><offsets xml_i="39441" xml_f="39555" txt_i="26760" txt_f="26874">]. The significance level will be set at 0.05. All statistical analysis will be performed using SPSS version 22.0.</offsets></p></sec><sec id="Sec18"><title><offsets xml_i="39588" xml_f="39602" txt_i="26876" txt_f="26890">Ethical issues</offsets></title><p><offsets xml_i="39613" xml_f="40185" txt_i="26891" txt_f="27463">The study protocol followed the principles of the Declaration of Helsinki and was approved by the research ethics committee (Protocol 925.406 by Instituto de Cardiologia do RS/Fundação Universitária de Cardiologia – Brazil, dated 22 December 2014 and signed by Dr. Leonardo Martins Pires). Furthermore, all subjects will read and give their informed consent for participation in the research study. All information will be confidential, subjects’ names will be kept confidential, and data will be collected for academic purposes only according to Resolution CNS N1466/12 [</offsets><xref ref-type="bibr" rid="CR50"><offsets xml_i="40218" xml_f="40220" txt_i="27463" txt_f="27465">50</offsets></xref><offsets xml_i="40227" xml_f="40523" txt_i="27465" txt_f="27761">]. If subjects in the RT and CT groups do not show any improvements of endothelial function (primary endpoint) or BP levels compared to those in the AT group, they will be offered the opportunity to practice the AT protocol after completion of the study to ensure equal benefits for all subjects.</offsets></p></sec></sec><sec id="Sec19"><title><offsets xml_i="40562" xml_f="40572" txt_i="27764" txt_f="27774">Discussion</offsets></title><p><offsets xml_i="40583" xml_f="40903" txt_i="27775" txt_f="28095">The Study of Endothelial Function Response to Exercise Training (SEFRET) is a single-site study that will be conducted in the city of Porto Alegre, Brazil. The study will be conducted in accordance with the principles of Good Clinical Practice and all requirements established by ICFUC relevant bodies and collaborators.</offsets></p><p><offsets xml_i="40910" xml_f="41526" txt_i="28096" txt_f="28712">The study results are expected to provide evidence of cardiovascular protective effects of different types of exercise training by modulating endothelial function in individuals with SAH. Knowing the magnitude of improvement of endothelium-dependent vasodilation by different types of exercise training can provide scientific evidence to the prescription of exercise programs for vascular protection targeted to hypertensive individuals. An adequate exercise program can lead to significant changes in cardiovascular function and promote health benefits and BP control, thus reducing adverse cardiovascular outcomes.</offsets></p><sec id="Sec20"><title><offsets xml_i="41553" xml_f="41572" txt_i="28713" txt_f="28732">Trial status report</offsets></title><p><offsets xml_i="41583" xml_f="41594" txt_i="28733" txt_f="28744">Recruiting.</offsets></p></sec></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>ABPM</term><def><p>ambulatory blood pressure monitoring</p></def></def-item><def-item><term>AT</term><def><p>aerobic training</p></def></def-item><def-item><term>BMI</term><def><p>body mass index</p></def></def-item><def-item><term>BP</term><def><p>pressure blood</p></def></def-item><def-item><term>CT</term><def><p>combined training</p></def></def-item><def-item><term>DBP</term><def><p>diastolic blood pressure</p></def></def-item><def-item><term>ECG</term><def><p>electrocardiogram</p></def></def-item><def-item><term>eNOS</term><def><p>endothelial nitric oxide synthase</p></def></def-item><def-item><term>ESR</term><def><p>erythrocyte sedimentation rate</p></def></def-item><def-item><term>FMD</term><def><p>flow-mediated dilation</p></def></def-item><def-item><term>FUC</term><def><p>Fundação Universitária de Cardiologia</p></def></def-item><def-item><term>HDL</term><def><p>high-density cholesterol</p></def></def-item><def-item><term>HRR</term><def><p>heart rate reserve</p></def></def-item><def-item><term>IC</term><def><p>Instituto de Cardiologia</p></def></def-item><def-item><term>IPAQ</term><def><p>International Physical Activity Questionnaire</p></def></def-item><def-item><term>LDL</term><def><p>low-density cholesterol</p></def></def-item><def-item><term>NO</term><def><p>nitric oxide</p></def></def-item><def-item><term>PBMN</term><def><p>Peripheral blood mononuclear cells</p></def></def-item><def-item><term>PBS</term><def><p>phosphate buffered saline</p></def></def-item><def-item><term>PCs</term><def><p>Progenitor cells</p></def></def-item><def-item><term>RBC</term><def><p>red blood cell</p></def></def-item><def-item><term>RT</term><def><p>resistance training</p></def></def-item><def-item><term>SAH</term><def><p>systemic arterial hypertension</p></def></def-item><def-item><term>SBP</term><def><p>systolic blood pressure</p></def></def-item><def-item><term>WHO</term><def><p>World Health Organization</p></def></def-item><def-item><term>1-RM</term><def><p>one repetition maximum.</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Competing interests</bold></p><p>The authors declare that they have no competing interests.</p></fn><fn><p><bold>Authors’ contributions</bold></p><p>MP and AML conceived and designed the research study and were involved with the preparation, organization, and registration of the study and obtaining approval from the local research ethics committee. MP, AML and IC will participate in the selection, recruitment and assessment of study subjects. MP will be the principal investigator. GW and AC will be members of the exercise training team. GW, MMM, and IC will also contribute to the analysis and interpretation of the data. All authors will participate in drafting and revising the manuscript for intellectual content and will review and approve the final manuscript before submission.</p></fn></fn-group><ack><p>The authors thank Carla Finger for English assistance and Dr. Walter Nisa Castro Neto for statistical expertise.</p><p>The project will be funded by FAPPIC (Fundo de Apoio à Pesquisa do Instituto de Cardiologia / Fundação Universitária de Cardiologia).</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paffenbarger</surname><given-names>RS</given-names><suffix>Jr</suffix></name><name><surname>Jung</surname><given-names>DL</given-names></name><name><surname>Leung</surname><given-names>RW</given-names></name><name><surname>Hyde</surname><given-names>RT</given-names></name></person-group><article-title>Physical activity and hypertension: an epidemiological view</article-title><source>Ann Med.</source><year>1991</year><volume>23</volume><fpage>319</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.3109/07853899109148067</pub-id><pub-id pub-id-type="pmid">1930924</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fagard</surname><given-names>RH</given-names></name></person-group><article-title>Physical activity, physical fitness and the incidence of hypertension</article-title><source>J Hypertens.</source><year>2005</year><volume>23</volume><issue>2</issue><fpage>265</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1097/00004872-200502000-00005</pub-id><pub-id pub-id-type="pmid">15662211</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><mixed-citation publication-type="other">Obesity: preventing and managing the global epidemic: report of a WHO Consultation on Obesity, Geneva, 3–5 June 1997. <ext-link ext-link-type="uri" xlink:href="https://extranet.who.int/iris/restricted/handle/10665/63854?mode=full">https://extranet.who.int/iris/restricted/handle/10665/63854?mode=full</ext-link>. Accessed 25 Nov 2014.</mixed-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Simone</surname><given-names>G</given-names></name><name><surname>Devereux</surname><given-names>RB</given-names></name><name><surname>Chinali</surname><given-names>M</given-names></name><name><surname>Roman</surname><given-names>MJ</given-names></name><name><surname>Best</surname><given-names>LG</given-names></name><name><surname>Welty</surname><given-names>TK</given-names></name><etal></etal></person-group><article-title>Strong Heart Study. Risk Factors for Arterial Hypertension in Adults With Initial Optimal Blood Pressure</article-title><source>Hypertension.</source><year>2006</year><volume>47</volume><issue>2</issue><fpage>162</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1161/01.HYP.0000199103.40105.b5</pub-id><pub-id pub-id-type="pmid">16380527</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seligman</surname><given-names>BG</given-names></name><name><surname>Polanczyk</surname><given-names>CA</given-names></name><name><surname>Santos</surname><given-names>AS</given-names></name><name><surname>Foppa</surname><given-names>M</given-names></name><name><surname>Junges</surname><given-names>M</given-names></name><name><surname>Bonzanini</surname><given-names>L</given-names></name><etal></etal></person-group><article-title>Intensive practical lifestyle intervention improves endothelial function in metabolic syndrome independent of weight loss: a randomized controlled trial</article-title><source>Metabolism.</source><year>2011</year><volume>60</volume><fpage>1736</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1016/j.metabol.2011.05.006</pub-id><pub-id pub-id-type="pmid">21700302</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hatzis</surname><given-names>G</given-names></name><name><surname>Tousoulis</surname><given-names>D</given-names></name><name><surname>Papageorgiou</surname><given-names>N</given-names></name><name><surname>Bouras</surname><given-names>G</given-names></name><name><surname>Oikonomou</surname><given-names>E</given-names></name><name><surname>Miliou</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>Combined effects of smoking and interleukin-6 and C-reactive protein genetic variants on endothelial function, inflammation, thrombosis and incidence of coronary artery disease</article-title><source>Int J Cardiol.</source><year>2014</year><volume>176</volume><fpage>254</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1016/j.ijcard.2014.06.058</pub-id><pub-id pub-id-type="pmid">25027167</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fahs</surname><given-names>CA</given-names></name><name><surname>Smith</surname><given-names>DL</given-names></name><name><surname>Horn</surname><given-names>GP</given-names></name><name><surname>Agiovlasitis</surname><given-names>S</given-names></name><name><surname>Rossow</surname><given-names>LM</given-names></name><name><surname>Echols</surname><given-names>G</given-names></name><etal></etal></person-group><article-title>Impact of excess body weight on arterial structure, function, and blood pressure in firefighters</article-title><source>Am J Cardiol.</source><year>2009</year><volume>104</volume><fpage>1441</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1016/j.amjcard.2009.07.009</pub-id><pub-id pub-id-type="pmid">19892065</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><mixed-citation publication-type="other">Belin de Chantemele EJ, Stepp DW. Influence of obesity and metabolic dysfunction on the endothelial control in the coronary circulation. J Mol Cell Cardiol. 2012; 52840–7.</mixed-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nosova</surname><given-names>EV</given-names></name><name><surname>Yen</surname><given-names>P</given-names></name><name><surname>Chong</surname><given-names>KC</given-names></name><name><surname>Alley</surname><given-names>HF</given-names></name><name><surname>Stock</surname><given-names>EO</given-names></name><name><surname>Quinn</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>Short-term physical inactivity impairs vascular function</article-title><source>J Surg Res.</source><year>2014</year><volume>190</volume><fpage>672</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1016/j.jss.2014.02.001</pub-id><pub-id pub-id-type="pmid">24630521</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kubisz</surname><given-names>P</given-names></name><name><surname>Stančiaková</surname><given-names>L</given-names></name><name><surname>Staško</surname><given-names>J</given-names></name><name><surname>Galajda</surname><given-names>P</given-names></name><name><surname>Mokáň</surname><given-names>M</given-names></name></person-group><article-title>Endothelial and platelet markers in diabetes mellitus type 2</article-title><source>World J Diabetes.</source><year>2015</year><volume>6</volume><fpage>423</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.4239/wjd.v6.i3.423</pub-id><pub-id pub-id-type="pmid">25897353</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soloviev</surname><given-names>MA</given-names></name><name><surname>Kulakova</surname><given-names>NV</given-names></name><name><surname>Semiglazova</surname><given-names>TA</given-names></name><name><surname>Borodulina</surname><given-names>EV</given-names></name><name><surname>Udut</surname><given-names>VV</given-names></name></person-group><article-title>Correction of endothelial dysfunction in patients with arterial hypertension</article-title><source>Bull Exp Biol Med.</source><year>2011</year><volume>151</volume><fpage>183</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1007/s10517-011-1284-1</pub-id><pub-id pub-id-type="pmid">22238745</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>TJ</given-names></name><name><surname>Uehata</surname><given-names>A</given-names></name><name><surname>Gerhard</surname><given-names>MD</given-names></name><name><surname>Meredith</surname><given-names>IT</given-names></name><name><surname>Knab</surname><given-names>S</given-names></name><name><surname>Delagrange</surname><given-names>D</given-names></name><etal></etal></person-group><article-title>Close relation of endothelial function in the human coronary and peripheral circulations</article-title><source>J Am Coll Cardiol.</source><year>1995</year><volume>26</volume><fpage>1235</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1016/0735-1097(95)00327-4</pub-id><pub-id pub-id-type="pmid">7594037</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tomiyama</surname><given-names>H</given-names></name><name><surname>Yamashina</surname><given-names>A</given-names></name></person-group><article-title>Non-invasive vascular function tests: their pathophysiological background and clinical application</article-title><source>Circ J.</source><year>2010</year><volume>74</volume><fpage>24</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1253/circj.CJ-09-0534</pub-id><pub-id pub-id-type="pmid">19920359</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Félétou</surname><given-names>M</given-names></name><name><surname>Vanhoutte</surname><given-names>PM</given-names></name></person-group><article-title>Endothelial dysfunction: a multifaceted disorder (The Wiggers Award Lecture)</article-title><source>Am J Physiol Heart Circ Physiol.</source><year>2006</year><volume>291</volume><fpage>H985</fpage><lpage>1002</lpage><pub-id pub-id-type="doi">10.1152/ajpheart.00292.2006</pub-id><pub-id pub-id-type="pmid">16632549</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jenkins</surname><given-names>NT</given-names></name><name><surname>Padilla</surname><given-names>J</given-names></name><name><surname>Boyle</surname><given-names>LJ</given-names></name><name><surname>Credeur</surname><given-names>DP</given-names></name><name><surname>Laughlin</surname><given-names>MH</given-names></name><name><surname>Fadel</surname><given-names>PJ</given-names></name></person-group><article-title>Disturbed blood flow acutely induces activation and apoptosis of the human vascular endothelium</article-title><source>Hypertension.</source><year>2013</year><volume>61</volume><fpage>615</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.111.00561</pub-id><pub-id pub-id-type="pmid">23319545</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalka</surname><given-names>C</given-names></name><name><surname>Masuda</surname><given-names>H</given-names></name><name><surname>Takahashi</surname><given-names>T</given-names></name><name><surname>Kalka-Moll</surname><given-names>WM</given-names></name><name><surname>Silver</surname><given-names>M</given-names></name><name><surname>Kearney</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization</article-title><source>Proc Natl Acad Sci U S A.</source><year>2000</year><volume>97</volume><fpage>3422</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1073/pnas.97.7.3422</pub-id><pub-id pub-id-type="pmid">10725398</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vasa</surname><given-names>M</given-names></name><name><surname>Fichtlscherer</surname><given-names>S</given-names></name><name><surname>Aicher</surname><given-names>A</given-names></name><name><surname>Adler</surname><given-names>K</given-names></name><name><surname>Urbich</surname><given-names>C</given-names></name><name><surname>Martin</surname><given-names>H</given-names></name><etal></etal></person-group><article-title>Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease</article-title><source>Circ Res.</source><year>2001</year><volume>89</volume><fpage>E1</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1161/hh1301.093953</pub-id><pub-id pub-id-type="pmid">11440984</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hill</surname><given-names>JM</given-names></name><name><surname>Zalos</surname><given-names>G</given-names></name><name><surname>Halcox</surname><given-names>JP</given-names></name><name><surname>Schenke</surname><given-names>WH</given-names></name><name><surname>Waclawiw</surname><given-names>MA</given-names></name><name><surname>Quyyumi</surname><given-names>AA</given-names></name><etal></etal></person-group><article-title>Circulating endothelial progenitor cells, vascular function, and cardiovascular risk</article-title><source>N Engl J Med.</source><year>2003</year><volume>348</volume><fpage>593</fpage><lpage>600</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa022287</pub-id><pub-id pub-id-type="pmid">12584367</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Werner</surname><given-names>N</given-names></name><name><surname>Kosiol</surname><given-names>S</given-names></name><name><surname>Schiegl</surname><given-names>T</given-names></name><name><surname>Ahlers</surname><given-names>P</given-names></name><name><surname>Walenta</surname><given-names>K</given-names></name><name><surname>Link</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>Circulating endothelial progenitor cells and cardiovascular outcomes</article-title><source>N Engl J Med.</source><year>2005</year><volume>353</volume><fpage>999</fpage><lpage>1007</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa043814</pub-id><pub-id pub-id-type="pmid">16148285</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>GX</given-names></name><name><surname>Zhang</surname><given-names>XY</given-names></name><name><surname>Xia</surname><given-names>WH</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Su</surname><given-names>C</given-names></name><etal></etal></person-group><article-title>Lacidipine improves endothelial repair capacity of endothelial progenitor cells from patients with essential hypertension</article-title><source>Int J Cardiol.</source><year>2013</year><volume>168</volume><fpage>3317</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1016/j.ijcard.2013.04.041</pub-id><pub-id pub-id-type="pmid">23642821</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Puls</surname><given-names>M</given-names></name><name><surname>Schroeter</surname><given-names>MR</given-names></name><name><surname>Steier</surname><given-names>J</given-names></name><name><surname>Stijohann</surname><given-names>L</given-names></name><name><surname>Hasenfuss</surname><given-names>G</given-names></name><name><surname>Konstantinides</surname><given-names>S</given-names></name><etal></etal></person-group><article-title>Effect of smoking cessation on the number and adhesive properties of early outgrowth endothelial progenitor cells</article-title><source>Int J Cardiol.</source><year>2011</year><volume>152</volume><fpage>61</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.ijcard.2010.07.007</pub-id><pub-id pub-id-type="pmid">21093936</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Devaraj</surname><given-names>S</given-names></name><name><surname>Jialal</surname><given-names>I</given-names></name></person-group><article-title>Dysfunctional endothelial progenitor cells in metabolic syndrome</article-title><source>Exp Diabetes Res.</source><year>2012</year><volume>2012</volume><fpage>585018</fpage><pub-id pub-id-type="doi">10.1155/2012/585018</pub-id><pub-id pub-id-type="pmid">21941528</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>António</surname><given-names>N</given-names></name><name><surname>Fernandes</surname><given-names>R</given-names></name><name><surname>Soares</surname><given-names>A</given-names></name><name><surname>Soares</surname><given-names>F</given-names></name><name><surname>Lopes</surname><given-names>A</given-names></name><name><surname>Carvalheiro</surname><given-names>T</given-names></name><etal></etal></person-group><article-title>Reduced levels of circulating endothelial progenitor cells in acute myocardial infarction patients with diabetes or pre-diabetes: accompanying the glycemic continuum</article-title><source>Cardiovasc Diabetol.</source><year>2014</year><volume>13</volume><fpage>101</fpage><pub-id pub-id-type="doi">10.1186/1475-2840-13-101</pub-id><pub-id pub-id-type="pmid">24934236</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zerbini</surname><given-names>G</given-names></name><name><surname>Lorenzi</surname><given-names>M</given-names></name><name><surname>Palini</surname><given-names>A</given-names></name></person-group><article-title>Tumor angiogenesis</article-title><source>N Engl J Med.</source><year>2008</year><volume>359</volume><fpage>763</fpage><pub-id pub-id-type="doi">10.1056/NEJMc081278</pub-id><pub-id pub-id-type="pmid">18703484</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>James</surname><given-names>PA</given-names></name><name><surname>Oparil</surname><given-names>S</given-names></name><name><surname>Carter</surname><given-names>BL</given-names></name><name><surname>Cushman</surname><given-names>WC</given-names></name><name><surname>Dennison-Himmelfarb</surname><given-names>C</given-names></name><name><surname>Handler</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)</article-title><source>JAMA.</source><year>2014</year><volume>311</volume><fpage>507</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1001/jama.2013.284427</pub-id><pub-id pub-id-type="pmid">24352797</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ficker</surname><given-names>ES</given-names></name><name><surname>Maranhão</surname><given-names>RC</given-names></name><name><surname>Chacra</surname><given-names>AP</given-names></name><name><surname>Neves</surname><given-names>VC</given-names></name><name><surname>Negrão</surname><given-names>CE</given-names></name><name><surname>Martins</surname><given-names>VC</given-names></name><etal></etal></person-group><article-title>Exercise training accelerates the removal from plasma of LDL-like nanoemulsion in moderately hypercholesterolemic subjects</article-title><source>Atherosclerosis.</source><year>2010</year><volume>212</volume><fpage>230</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2010.04.030</pub-id><pub-id pub-id-type="pmid">20627247</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silva</surname><given-names>JF</given-names></name><name><surname>Rocha</surname><given-names>NG</given-names></name><name><surname>Nóbrega</surname><given-names>AC</given-names></name></person-group><article-title>Mobilization of endothelial progenitor cells with exercise in healthy individuals: a systematic review</article-title><source>Arq Bras Cardiol.</source><year>2012</year><volume>98</volume><fpage>182</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">22378336</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Volaklis</surname><given-names>KA</given-names></name><name><surname>Tokmakidis</surname><given-names>SP</given-names></name><name><surname>Halle</surname><given-names>M</given-names></name></person-group><article-title>Acute and chronic effects of exercise on circulating endothelial progenitor cells in healthy and diseased patients</article-title><source>Clin Res Cardiol.</source><year>2013</year><volume>102</volume><fpage>249</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1007/s00392-012-0517-2</pub-id><pub-id pub-id-type="pmid">23117697</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frank</surname><given-names>P</given-names></name><name><surname>Andersson</surname><given-names>E</given-names></name><name><surname>Pontén</surname><given-names>M</given-names></name><name><surname>Ekblom</surname><given-names>B</given-names></name><name><surname>Ekblom</surname><given-names>M</given-names></name><name><surname>Sahlin</surname><given-names>K</given-names></name></person-group><article-title>Strength training improves muscle aerobic capacity and glucose tolerance in elderly</article-title><source>Scand J Med Sci Sports</source><year>2015</year></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Nigris</surname><given-names>V</given-names></name><name><surname>Pujadas</surname><given-names>G</given-names></name><name><surname>La Sala</surname><given-names>L</given-names></name><name><surname>Testa</surname><given-names>R</given-names></name><name><surname>Genovese</surname><given-names>S</given-names></name><name><surname>Ceriello</surname><given-names>A</given-names></name></person-group><article-title>Short-term high glucose exposure impairs insulin signaling in endothelial cells</article-title><source>Cardiovasc Diabetol.</source><year>2015</year><volume>14</volume><fpage>114</fpage><pub-id pub-id-type="doi">10.1186/s12933-015-0278-0</pub-id><pub-id pub-id-type="pmid">26297582</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>L</given-names></name><name><surname>Morrison</surname><given-names>JA</given-names></name><name><surname>Wiecha</surname><given-names>J</given-names></name><name><surname>Horton</surname><given-names>M</given-names></name><name><surname>Hayman</surname><given-names>LL</given-names></name></person-group><article-title>Healthylifestyle factors associated with reduced cardiometabolic risk</article-title><source>Br J Nutr.</source><year>2011</year><volume>105</volume><fpage>747</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1017/S0007114510004307</pub-id><pub-id pub-id-type="pmid">21276278</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montero</surname><given-names>D</given-names></name><name><surname>Walther</surname><given-names>G</given-names></name><name><surname>Benamo</surname><given-names>E</given-names></name><name><surname>Perez-Martin</surname><given-names>A</given-names></name><name><surname>Vinet</surname><given-names>A</given-names></name></person-group><article-title>Effects of exercise training on arterial function in type 2 diabetes mellitus: a systematic review and meta-analysis</article-title><source>Sports Med.</source><year>2013</year><volume>43</volume><fpage>1191</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1007/s40279-013-0085-2</pub-id><pub-id pub-id-type="pmid">23912806</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vuckovic</surname><given-names>KM</given-names></name><name><surname>Piano</surname><given-names>MR</given-names></name><name><surname>Phillips</surname><given-names>SA</given-names></name></person-group><article-title>Effects of Exercise Interventions on Peripheral Vascular Endothelial Vasoreactivity in Patients with Heart Failure with Reduced Ejection Fraction</article-title><source>Heart Lung Circ.</source><year>2013</year><volume>22</volume><fpage>328</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1016/j.hlc.2012.12.006</pub-id><pub-id pub-id-type="pmid">23340198</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cornelissen</surname><given-names>VA</given-names></name><name><surname>Smart</surname><given-names>NA</given-names></name></person-group><article-title>Exercise training for blood pressure: a systematic review and meta-analysis</article-title><source>J Am Heart Assoc.</source><year>2013</year><volume>2</volume><fpage>e004473</fpage><pub-id pub-id-type="doi">10.1161/JAHA.112.004473</pub-id><pub-id pub-id-type="pmid">23525435</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ribeiro</surname><given-names>AS</given-names></name><name><surname>Tomeleri</surname><given-names>CM</given-names></name><name><surname>Souza</surname><given-names>MF</given-names></name><name><surname>Pina</surname><given-names>FL</given-names></name><name><surname>Schoenfeld</surname><given-names>BJ</given-names></name><name><surname>Nascimento</surname><given-names>MA</given-names></name><name><surname>Venturini</surname><given-names>D</given-names></name><name><surname>Barbosa</surname><given-names>DS</given-names></name><name><surname>Cyrino</surname><given-names>ES</given-names></name></person-group><article-title>Effect of resistance training on C-reactive protein, blood glucose and lipid profile in older women with differing levels of RT experience</article-title><source>Age (Dordr)</source><year>2015</year><volume>37</volume><fpage>109</fpage><pub-id pub-id-type="doi">10.1007/s11357-015-9849-y</pub-id><pub-id pub-id-type="pmid">26499819</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corretti</surname><given-names>MC</given-names></name><name><surname>Anderson</surname><given-names>TJ</given-names></name><name><surname>Benjamin</surname><given-names>EJ</given-names></name><name><surname>Celermajer</surname><given-names>D</given-names></name><name><surname>Charbonneau</surname><given-names>F</given-names></name><name><surname>Creager</surname><given-names>MA</given-names></name><etal></etal></person-group><article-title>Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force</article-title><source>J Am Coll Cardiol.</source><year>2002</year><volume>39</volume><fpage>257</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1016/S0735-1097(01)01746-6</pub-id><pub-id pub-id-type="pmid">11788217</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montezano</surname><given-names>AC</given-names></name><name><surname>Dulak-Lis</surname><given-names>M</given-names></name><name><surname>Tsiropoulou</surname><given-names>S</given-names></name><name><surname>Harvey</surname><given-names>A</given-names></name><name><surname>Briones</surname><given-names>AM</given-names></name><name><surname>Touyz</surname><given-names>RM</given-names></name></person-group><article-title>Oxidative stress and human hypertension: vascular mechanisms, biomarkers, and novel therapies</article-title><source>Can J Cardiol.</source><year>2015</year><volume>31</volume><fpage>631</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1016/j.cjca.2015.02.008</pub-id><pub-id pub-id-type="pmid">25936489</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidt-Lucke</surname><given-names>C</given-names></name><name><surname>Fichtlscherer</surname><given-names>S</given-names></name><name><surname>Aicher</surname><given-names>A</given-names></name><name><surname>Tschöpe</surname><given-names>C</given-names></name><name><surname>Schultheiss</surname><given-names>HP</given-names></name><name><surname>Zeiher</surname><given-names>AM</given-names></name><etal></etal></person-group><article-title>Quantification of circulating endothelial progenitor cells using the modified ISHAGE protocol</article-title><source>PLoS One.</source><year>2010</year><volume>5</volume><fpage>e13790</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0013790</pub-id><pub-id pub-id-type="pmid">21072182</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amabile</surname><given-names>N</given-names></name><name><surname>Cheng</surname><given-names>S</given-names></name><name><surname>Renard</surname><given-names>JM</given-names></name><name><surname>Larson</surname><given-names>MG</given-names></name><name><surname>Ghorbani</surname><given-names>A</given-names></name><name><surname>McCabe</surname><given-names>E</given-names></name><etal></etal></person-group><article-title>Association of circulating endothelial microparticles with cardiometabolic risk factors in the Framingham Heart Study</article-title><source>Eur Heart J.</source><year>2014</year><volume>35</volume><fpage>2972</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehu153</pub-id><pub-id pub-id-type="pmid">24742886</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Sociedade Brasileira de Cardiologia, Sociedade Brasileira de Hipertensão, Sociedade Brasileira de Nefrologia</collab></person-group><article-title>VI Brazilian Guidelines on Hypertension</article-title><source>Arq Bras Cardiol</source><year>2010</year><volume>95</volume><issue>Suppl 1</issue><fpage>1</fpage><lpage>51</lpage></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sorensen</surname><given-names>KE</given-names></name><name><surname>Celermajer</surname><given-names>DS</given-names></name><name><surname>Spiegelhalter</surname><given-names>DJ</given-names></name><name><surname>Georgakopoulos</surname><given-names>D</given-names></name><name><surname>Robinson</surname><given-names>J</given-names></name><name><surname>Thomas</surname><given-names>O</given-names></name><etal></etal></person-group><article-title>Non-invasive measurement of human endothelium dependent arterial responses: accuracy and reproducibility</article-title><source>Br Heart J.</source><year>1995</year><volume>74</volume><fpage>247</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1136/hrt.74.3.247</pub-id><pub-id pub-id-type="pmid">7547018</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ciconelli</surname><given-names>RM</given-names></name><name><surname>Soarez</surname><given-names>PC</given-names></name><name><surname>Kowalski</surname><given-names>CC</given-names></name><name><surname>Ferraz</surname><given-names>MB</given-names></name></person-group><article-title>The Brazilian Portuguese version ofthe Work Productivity and Activity Impairment: General Health (WPAI-GH) Questionnaire</article-title><source>São Paulo Med J.</source><year>2006</year><volume>124</volume><fpage>325</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1590/S1516-31802006000600005</pub-id><pub-id pub-id-type="pmid">17322953</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><mixed-citation publication-type="other">Waclawovsky G, Umpierre D, Figueira FR, de Lima ES, Alegretti AP, Schneider L, et al. Exercise on Progenitor Cells in Healthy Subjects and Patients with Type 1 Diabetes. Med Sci Sports Exerc. 2015 [Epub ahead of print].</mixed-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schiro</surname><given-names>A</given-names></name><name><surname>Wilkinson</surname><given-names>FL</given-names></name><name><surname>Weston</surname><given-names>R</given-names></name><name><surname>Smyth</surname><given-names>JV</given-names></name><name><surname>Serracino-Inglott</surname><given-names>F</given-names></name><name><surname>Alexander</surname><given-names>MY</given-names></name></person-group><article-title>Elevated levels of endothelial-derived microparticles, and serum CXCL9 and SCGF-β are associated with unstable asymptomatic carotid plaques</article-title><source>Sci Rep.</source><year>2015</year><volume>5</volume><fpage>16658</fpage><pub-id pub-id-type="doi">10.1038/srep16658</pub-id><pub-id pub-id-type="pmid">26564003</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Sociedade Brasileira de Cardiologia</collab></person-group><article-title>III Guidelines of Sociedade Brasileira de Cardiologia on the exercise test</article-title><source>Arq Bras Cardiol</source><year>2010</year><volume>95</volume><issue>5 Suppl 1</issue><fpage>1</fpage><lpage>26</lpage></element-citation></ref><ref id="CR46"><label>46.</label><mixed-citation publication-type="other">Baechle T, Earle R. Essentials of Strength Training and Conditioning. 3rd ed. Champaigne: Human Kinetics; 2008.</mixed-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borg</surname><given-names>G</given-names></name></person-group><article-title>Psychophysical basis of perceived exertion</article-title><source>Med Sci Sports Exerc.</source><year>1982</year><volume>14</volume><fpage>377</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">7154893</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Colberg</surname><given-names>SR</given-names></name></person-group><source>Exercise and Diabetes: A Clinician's Guide to Prescribing Physical Activity</source><year>2013</year><publisher-loc>Alexandria</publisher-loc><publisher-name>American Diabetes Association</publisher-name></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Zar</surname><given-names>JH</given-names></name></person-group><source>Biostatistical Analysis</source><year>1999</year><edition>4</edition><publisher-loc>Prentice Hall</publisher-loc><publisher-name>Upper Saddle River</publisher-name></element-citation></ref><ref id="CR50"><label>50.</label><mixed-citation publication-type="other">Conselho Nacional de Saúde (Brasil). Resolução n<sup>o</sup> 466, de 12 de dezembro de 2012. Brasília, 2012 [citado 2014 Mar 11]. <ext-link ext-link-type="uri" xlink:href="http://www.conselho.saude.gov.br/web_comissoes/conep/index.html">http://www.conselho.saude.gov.br/web_comissoes/conep/index.html</ext-link>. Accessed 4 January 2014.</mixed-citation></ref></ref-list></back></article>